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Autoimmune disorders are a challenging problem for both afflicted patients and 
pharmaceutical scientists, since they involve one of the most complex biological systems – the 
immune system. A dysregulation of antigen recognition is at the center of autoimmune disorders, 
and can occur in a variety of host tissues throughout the body. Further complicating these diseases 
is the high degree of variability in terms of clinical manifestation. Traditional therapies for 
autoimmune disorders, such as corticosteroids or immunomodulators, generally focus on symptom 
suppression or slowing disease progression rather than treating the underlying cause, which is 
rarely fully understood. New approaches to treatments in which a disease-causing autoantigen is 
known seek to leverage antigen specificity through the development of antigen-specific 
immunotherapies (ASIT). 
In this research, we explore different novel approaches to ASIT focused on chemical 
conjugation, including the design and development of a new therapeutic class, antigen-drug 
conjugates (AgDCs). By reversing the paradigm of antibody-drug conjugates (ADCs), AgDCs 
exploit the directing effect of the autoantigen towards diseased cell populations, coupled with the 
immunomodulatory effects of a small molecule drug. Soluble Antigen Arrays (SAgAs) focus on 
disrupting immune recognition at the immunological synapse by conjugating autoantigen on a 
multivalent polymer support. Polymer-drug conjugates also present a unique opportunity as a 
depot delivery system with the potential for targeted applications. The strategies presented here 
carry an overarching goal to increase therapeutic specificity while limiting off-target effects, in an 
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CHAPTER 1:  INTRODUCTION TO AUTOIMMUNE DISORDERS AND CURRENT TREATMENT 
APPROACHES 
1.1. Introduction to autoimmune disorders 
Autoimmune disorders are a dysfunction of the immune system, and the National Institutes 
of Health (NIH) estimate that autoimmune disorders affect more than 23.5 million Americans with 
more than 80 currently documented diseases. The adaptive immune response is dependent on 
recognition of target antigens, and autoimmune disease occurs when the body fails to maintain 
tolerance toward self-antigens.1 These self-antigens can be present in a number of host tissues in 
various organs, leading to diseases such as multiple sclerosis (MS), myasthenia gravis, diabetes 
mellitus type 1, and myocarditis.2 Autoimmune reactions are highly complex and variable, relying 
on a network of interacting cells and biomolecules to shape downstream responses. While the 
immune system has both central and peripheral tolerance mechanisms to prevent immune reactions 
to native antigens,1 autoimmunity can still occur and require therapeutic intervention.   
 One of the most prevalent autoimmune disorders is MS, a chronic inflammatory and 
demyelinating disease leading to significant neurological disability in patients, with symptoms 
including cognitive impairment, motor or sensory disturbances, weakness, pain and fatigue.3 A 
major challenge in MS is the heterogeneous clinical presentation of disease, generally correlating 
with the hallmark white matter lesions of the central nervous system (CNS).4-5 While full 
elucidation of the pathogenic mechanisms behind MS is not complete, the current understanding 
is that myelin sheath proteins that insulate axons in the CNS likely act as the autoantigens which 
propagate the immune response. Proteolipid protein (>50%) and myelin basic protein (15%) are 
the most abundant protein components of CNS myelin,6 and have been successfully used to induce 
a chronic demyelinating condition in a murine model of MS, experimental autoimmune 
encephalomyelitis (EAE).7-8 Recruitment of peripheral immune cells across the blood-brain barrier 
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in response to CNS myelin autoantigens is a major therapeutic target for MS, although treatments 
continue to evolve as our mechanistic understanding progresses.9-10   
 
1.2. Current treatment approaches for autoimmune disorders 
Immunomodulatory agents and hyposensitization therapy are the two general treatment 
strategies clinically evaluated for autoimmune disease. Immunomodulatory agents have been 
effective, but suffer from systemic action and subsequent global immunosuppression, which can 
increase the vulnerability to opportunistic infections in immunocompromised patient 
populations.11 In addition to general immunosuppressants, transport inhibitors and inhibitors of 
immune cell activation also exist, with the general drawback of lacking antigen specificity.  
Importantly, immunomodulators used to treat autoimmune disorders generally target symptom 
suppression or reduction of disease progression, and do not substantially halt or reverse disease.12-
13 Hyposensitization therapy involves multiple administrations of antigen in low but increasing 
doses and has proven effective at inducing immune tolerance to allergens through modulation of 
T cell and B cell responses,14 but have shown minimal efficacy in clinical trials for autoimmune 
disease.11 Related to hyposensitization therapy is the use of antigen mimics, which have the 
potential to provide a ‘decoy’ effect for the immune system, distracting antigen-specific immune 
cells from attacking host tissues.11 Of these overall strategies, a pressing need exists to improve 




1.3. Antigen-specific immunotherapy (ASIT) 
By combining the specificity of hyposensitization therapy with the potency of 
immunomodulatory drugs, the potential to achieve a synergistic effect necessary to induce antigen-
specific immune tolerance in autoimmune disease exists, giving rise to antigen-specific 
immunotherapy (ASIT). Successfully piloted in several models of autoimmune disease,15-16 the 
strategy of co-administering a drug and autoantigen provides a unique approach to treating 
autoimmune disorders. Furthermore, ASIT has implications in both the treatment and prophylaxis 
of disease,17 and the potential to obviate the need for extended treatment schedules, which often 
lead to decreased patient compliance. 
Two general strategies for ASIT exist, co-administration and co-delivery, each with their 
own advantages and drawbacks. Co-administration benefits from simplicity - the components do 
not require co-formulation and can even employ different routes of administration, easing the 
formulation and regulatory burden during development. This permits for the utilization of two 
currently approved products without the need for additional clinical development. However, 
effective treatment of disease may require spatiotemporal regulation of both entities, which can be 
difficult to ensure in the absence of a mechanism to promote co-localization.11 While the 
treatments may provide a synergistic effect, it is possible that the addition of a delivery vehicle 
would result in improved therapeutic efficacy.  
Co-delivery has distinct advantages over co-administration by eliminating potential 
variability in trafficking of the components due to differences in molecular properties or routes of 
administration, and can potentiate an inflammatory response rather than the desired tolerogenic 
response.11 In the absence of a delivery vehicle, it can be difficult to maintain the desired 
therapeutic specificity of this approach, however, when co-delivery vehicles such as micelles, 
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polymers, or liposomes are included in the formulation, the heterogeneous nature of the 
composition brings added challenges in terms of reproducibility and analysis. The alternative is 
chemical modification, linking the drug molecule to the carrier with a stable covalent bond, which 
greatly enhances the probability of achieving the necessary spatial and temporal regulation without 
the need for additional excipients or formulation approaches. While the delivery vehicle and 
covalent modification strategies have seen both clinical and commercial success,18-19 chemical 
conjugation has the potential to provide a better defined chemical entity when compared to those 
encapsulated in a delivery vehicle,20 and is the focus here. 
 
1.4. Clinical precedence of immune cell targeting using ASIT co-delivery: antibody-drug 
conjugates (ADCs) 
Covalent modification of potent drugs to biomolecule carriers has exhibited significant 
interest in recent years with the commercialization of the first antibody-drug conjugates (ADCs), 
yielding a surge in clinical development.19, 21 ADCs exploit the specificity of the antibody carrier 
for cancerous cells, in conjunction with the high potency of their cytotoxic payloads. Upon 
internalization of the ADC, the drug is able to act inside the cancerous cells, while limiting the off-
target effects commonly associated with administration of the small molecule drug alone. ADCs 
are a comparable approach to ASIT, with a slight reversal in roles. In ADCs, the drug-linked 
antibody targets cell surface antigenic receptors. In the ASIT concept, the antigen is responsible 
for providing specificity by targeting cell surface antibody receptors, with the co-delivered drug 
providing the therapeutic effect. 
In some cases, installation of cleavable linker systems between the antibody and drug that 
respond to environmental stimuli present near the intended site of action, such as low pH, 
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oxidation/reducing conditions, or enzymatic cleavage, can aid in the targeted delivery of the drug. 
In other cases, the drug may still be active while conjugated to the antibody carrier. A number of 
different attachment strategies have been proposed18, 22-25 to enable each approach, with continued 
development leading to improved ADCs with increased therapeutic windows and safety profiles.19 
While the complexity and therapeutic heterogeneity have produced manufacturing and analytical 
hurdles, the clinical outcomes seen with ADCs warrant their continued advancement.21, 26-27 
Simply put, ADCs have greatly impacted cancer treatment and established the foundation for 
future development of novel bioconjugates with implications across the disease landscape. 
 
1.5. Overview of dissertation  
The focus of this dissertation is on developing novel therapeutics for the treatment of 
autoimmune disorders, using bioconjugation chemistries to accomplish this task. The 
concentration of the research presented here is on the design, synthesis, characterization, and 
stability of these conjugates. Work conducted by other graduate student researchers is included as 
a proof of concept in in vitro or in vivo systems, and credited as appropriate here and at the time 
of publication. 
Chapter 2 highlights a powerful conjugation chemistry, the azide-alkyne cycloaddition 
(AAC) reaction. While the catalyzed version of this reaction was only presented in 2001, a 
SciFinder search shows 5913 publications using the search term “azide alkyne cycloaddition” in 
the first 15 years (2001-2016), underlining the reaction’s importance to scientists in many different 
fields. Parallel to this development is the increasing commercial availability of drugs, probes and 
other functionalized molecules bearing azide and alkyne moieties for facile access to complex 
conjugates. The focus of this chapter is to provide an overview of the AAC reaction, chemistries 
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appropriate for installing azide and alkyne handles on a variety of different molecules, and the 
common challenges and limitations of the chemistry with key design considerations when 
constructing therapeutic bioconjugates. This covers the functionalization of small molecules, 
proteins, peptides, polymers, as well as their subsequent conjugates, and provides the basis for the 
chemistry employed throughout the rest of the dissertation. This will serve as the basis for a review 
article to be submitted to ACS Bioconjugate Chemistry. 
Chapter 3 focuses on the development of a novel class of compounds, antigen-drug 
conjugates (AgDCs). By reversing the paradigm of the emerging class of ADCs, AgDCs permits 
repurposing of this approach for different therapeutic indications. Most current ADCs employ an 
antibody specific for cell-surface antigens expressed on cancer cells, linked to a potent toxin for 
the targeted killing of cancerous cells. This approach provides greatly reduced off-target effects 
when compared with administering the drug alone, and enables the clinical application of payload 
toxins which are too potent for use as an individual treatment strategy. Utilizing the same targeting 
concept that the antibody provides, AgDCs link therapeutic molecules to peptide autoantigens in 
an effort to target antibody receptors present on offending immune cells responsible for disease. 
Importantly, AgDCs are a platform approach, expandable to a variety of antigen-specific 
autoimmune disorders. The goal of this work is to present this innovative therapeutic platform 
applied to the autoimmune disease MS, to promote the development of more efficacious 
immunotherapies with improved safety profiles and patient outcomes. 
Chapter 4 presents an extension of research conducted previously in the Berkland group as 
an alternative approach to the treatment of antigen-specific autoimmune disorders, termed Soluble 
Antigen Arrays (SAgAs).28-29 A key event involved in immune response is the formation of the 
immunological synapse (Figure 1), requiring co-stimulation of signals present on an antigen-
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presenting cell (APC) and a T cell, which triggers a cascade of downstream reactions that result in 
an inflammatory response and tissue damage.   
 
Figure 1: Proposed mechanism of action of SAgA therapeutics, with a particular focus on the immunological synapse. 
In this case, a polymeric support of hyaluronic acid co-grafted with a MS peptide autoantigen, 
proteolipid protein (PLP139-151), and a portion of intercellular adhesion molecule derived from 
CD11a237-246 (LABL) should effectively disrupt immune response. Mechanistic studies
30 support 
the hypothesis that receptor clustering induced by SAgA treatment can be an effective method of 
suppressing immune activation. The initial approach employed an acid-sensitive oxime bond 
between the polymeric support and peptides, and this work focused on modifications to the linkage 
to achieve a non-cleavable variant with improved aqueous stability. The hydrolytically stable 
version, termed ‘clickable’ Soluble Antigen Arrays (cSAgAs), showed improved efficacy31 in 
experimental autoimmune encephalomyelitis (EAE), a murine demyelinating model used to mimic 
MS in humans. 
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 Chapter 5 focuses on the development of a bioconjugate as a monotherapeutic replacement 
of two approved treatments which are currently co-administered and suffer from decreased 
efficacy due to poor patient compliance. Cataract surgeries frequently require the use of 
viscoelastic agents such as hyaluronic acid to maintain the integrity of the corneal endothelium, a 
monolayer of cells serving as an active fluid pump system and barrier. The current standard of care 
is phacoemulsification, widely known to cause corneal endothelial cell loss (ECL), which can be 
limited through the use of viscoelastic agents to stabilize the anterior chamber and limit damage 
by free radicals. Additionally, the management of post-operative intraocular inflammation through 
the use of anti-inflammatory agents is common, requiring frequent administration of topical 
solutions for extended periods of time. This chapter targets the development of a conjugate of 
hyaluronic acid linked to the anti-inflammatory compound dexamethasone as an extended release 
version to increase patient outcomes following cataract surgeries, particularly in elderly patient 
populations where compliance can be a concern.  
 Chapter 6 presents the conclusions from this dissertation research, with a particular focus 
on areas of improvement for the therapeutic bioconjugates presented, including ideas on expansion 
of the approaches to new indications and applications. The hope is that this chapter can present a 
guide for future scientists to improve or expand upon this work, creating new treatments with 
improved safety profiles and patient outcomes. The ideas contained in this chapter are a blend of 
many scientific fields, from chemistry and biology to engineering and immunology, thereby 
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CHAPTER 2: INTRODUCTION TO BIOCONJUGATION VIA AZIDE-ALKYNE CYCLOADDITION: 
CHALLENGES, CONSIDERATIONS, AND LIMITATIONS 
2.1. Introduction 
With the recent surge in the development of therapeutic bioconjugates, synthetic chemists 
have worked in parallel with biochemists to identify strategies for improving the specificity of the 
chemical modification. As the field of antibody-drug conjugates continues to emerge, chemical 
modifications with increasing specificity aide in enhancing bioconjugate homogeneity, therapeutic 
index, and other pharmacokinetic parameters, resulting in a safer and more effective treatment 
option for the patient. While historically, the construction of bioconjugates has employed 
numerous different chemistries, the focus of this chapter will be on the [3+2] cycloaddition 
reaction between an azide and an alkyne, with chemistries and methods appropriate for installation 
of these functionalities on proteins, peptides, polymers, small molecules, and cellular components 
in vivo. 
There are a number of published reviews and protocols that cover various approaches to 
conjugating small molecules to biomolecules in a selective fashion.32-34 While these reviews 
provide an excellent background on the implementation of these chemistries, the practical 
challenges and limitations of utilizing these chemistries in terms of relevant physiochemical 
properties of the conjugate will be discussed here. The reaction schemes presented in this section 
focus on the use of commercially-available reagents for both functionalization and conjugation. 
 
2.2. Azide-Alkyne Cycloaddition Reaction 
The formation of 1,2,3-triazoles was first studied by Huisgen in the 1960’s,35 but was later 
adapted to the copper-catalyzed azide alkyne cycloaddition (CuAAC) variant, developed 
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independently by the groups of Sharpless36 and Meldal37 in 2002. The addition of a copper catalyst 
preferentially formed the regiospecific 1,4-substituted triazole under mild reaction conditions and 
at rates 106-107 greater than the mixture of 1,4- and 1,5-substituted products in the absence of 
copper, which also necessitated the use of elevated reaction temperatures (Figure 2). Further work 
has shown that ruthenium complexes are capable of catalyzing the regioselective formation of 1,5-
substituted triazoles.38-39 A number of reviews,33 protocols,34 and mechanistic studies40-41 are 
available to provide further insight into the unprecedented reactivity of these molecules. 
The triazole ring is similar in both electronic properties and topology to a peptide bond, 
exhibiting a bond distance of ~ 5.0 Å as compared to 3.9 Å in the amide bond,42  and is stable 
under common biological stresses, including oxidizing or reducing conditions, enzymatic 
degradation, or pH. Facile synthesis of the triazole ring, in addition to its stability and chemical 
properties has been a significant driver of its implementation in bioconjugation applications. 
Outside of a biological system, however, the triazole ring has been reported to revert back to the 
parent azide and alkyne components under ultrasonication for 2 hours.43  
An initial surge in the application of the CuAAC reaction has identified a few drawbacks, 
primarily associated with the use of copper. The active catalytic species is Cu1+, but readily 
converts back to a more stable Cu2+ in solution, requiring in situ formation of Cu1+ using Cu2+ and 
excess reducing agent. Commonly, this reducing reagent is sodium ascorbate, and together with 
an active Cu1+, have been shown to promote the oxidation of histidine and arginine residues.44 
These unintended side reactions have led to the introduction of accelerating ligands to both limit 
degradation of these amino acids, in addition to accelerating the rate of the CuAAC reaction.40, 45 
Compounds like aminoguanidine are useful as a surrogate in cases were the biomolecule contains 
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arginine. Additionally, the toxic effect of copper on cells limits its use in cell based assays where 
long-term viability is a concern. 
 
Figure 2: General reaction scheme for the azide-alkyne cycloaddition under various conditions. 
 To alleviate the need for copper, accelerating ligands, reducing agents, and other stabilizing 
reagents, Bertozzi and coworkers developed the strain-promoted azide-alkyne cycloaddition 
reaction (SPAAC).46 The SPAAC reaction proceeds efficiently in the absence of a catalyst due to 
the high degree of ring strain on the cyclooctyne ring, under mild reaction conditions and times 
necessary for adaption to biomolecules (Figure 3A). The primary drawbacks of the SPAAC 
approach is the lack of regiospecificity of the reaction product, forming a mixture of 1,4- and 1,5-
substituted products. Initially, the aqueous solubility of the cyclooctyne reagents were of concern, 
but recent developments have seen the installation of solubilizing moieties such as PEG or sulfate 
groups in the linker attached to the ring. Furthermore, the cost of the strained cyclooctyne reagents 
is considerably higher than their terminal alkyne counterparts, but alternate synthetic routes47 are 
making SPAAC reagents more accessible and less cost-prohibitive to employ. Alternatively, a 
number of other strained alkyne moieties have been developed (Figure 3B) and shown to function 
as a coupling partner in the azide-alkyne click reaction, with varying reaction rates.48 Photolabile 
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“caged” cyclooctyne variants (Figure 3B, lower right) present an important added functionality to 
the reaction, revealing the reactive strained alkyne group under exposure to 350 nm light and 
enabling spatially-controlled conjugation.49 This approach is of particular interest in surface 
functionalization applications where spatiotemporal control of conjugation is critical.49-50 
 
Figure 3: (A) General reaction scheme for the strain-promoted azide-alkyne cycloaddition reaction. (B) Sample 




2.3.  Amidation using N-Hydroxysuccinimidyl (NHS) Esters 
NHS esters are among the most popular compounds used to functionalize biomolecules 
due to their aqueous compatibility, commercial availability, and selective targeting for primary 
amines present on lysine residues or the N-terminus (Figure 4). For biomolecules, reaction 
conditions generally employ aqueous buffers at pH 7-9. At a pH closer to 9, the reaction proceeds 
at a quicker rate due to a higher degree of amine deprotonation, but more hydrolysis of the activated 
ester prior to reacting with lysine residues is more problematic. At a pH closer to 7, the reaction 
proceeds at a slower rate, but favors reactions with primary amines rather than NHS ester 
hydrolysis by the aqueous environment. Intermediate pH’s between 7-9 are commonly employed 
to balance reaction rate and extent of functionalization while keeping the solubility and stability 
of the biomolecule in mind. Reactions performed at room temperature are usually complete in 1-
2 hours, while reactions involving more sensitive molecules can proceed at 4°C overnight. 
 
Figure 4: General reaction scheme for azide- or alkyne-labeling of a primary amine using NHS ester chemistry. 
Due to the difference in acidity between the α-amino group of the N-terminus (pKa ~ 8) 
and the ε-amino group of lysine residues (pKa ~ 10), selective N-terminal functionalization has 
been shown at pH values below 7, with pH 6.3 being ideal.51 Performing the reaction in the absence 
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of amine-containing buffers such as tris or glycine is essential, however, these can be useful as 
quenching buffers to ensure no additional reactive NHS ester is available after achieving the 
desired degree of functionalization. When possible, NHS ester reagent solutions that are prepared 
in anhydrous organic solvents are preferred to limit hydrolysis prior to initiating the reaction, 
provided that all reaction components remain compatible. NHS ester reagents are typically not 
stable for more than a few hours in solution, even when prepared in anhydrous solvents.  
 
Figure 5: General reaction scheme for azide- or alkyne-labeling of a carboxylic acid using NHS ester chemistry, 
where the coupling agent could be EDC or DCC depending on the reaction environment. 
For small molecules which do not necessitate an aqueous reaction environment, NHS ester 
reactions in anhydrous organic solvents such as N,N-dimethylformamide (DMF), 
dimethylsulfoxide (DMSO), acetonitrile (MeCN), and dichloromethane (CH2Cl2) are ideal. This 
generally results in higher yields and better selectivity for amino functional groups due to a 
reduction in aqueous hydrolysis. In the absence of amine functionality, NHS esters can also modify 
other nucleophilic groups in a molecule such as deprotonated hydroxyl or thiol moieties. 
Alternatively, NHS esters can functionalize carboxylic acids through in situ formation of the 
activated ester using NHS and an appropriate coupling reagent such as 1-ethyl-3-(3-




2.4. Thioether Formation to Install Azide and Alkyne Groups 
The thiol group on cysteine residues is commonly targeted using maleimide reagents, 
yielding a stable thioether bond and is an effective Michael addition reaction (Figure 6). Similar 
to the NHS ester, maleimide reactions are pH controlled in aqueous media, generally in the pH 
range of 6-8. At lower pH values, the reaction proceeds at a slower rate, but favors the thiol-
functionalization over hydrolysis. At higher pH values, the reaction proceeds at a faster rate, but 
hydrolysis of the maleimide is of greater concern. As with NHS esters, reaction buffers should 
avoid the use of thiols such as dithiothreitol (DTT) or β-mercaptoethanol (BME), but are useful 
post-reaction to quench any remaining maleimide after achieving the desired conjugation levels. 
 
Figure 6: General reaction scheme for azide- and alkyne-functionalization using maleimide chemistry. 
Mechanistic investigations of the thiol-maleimide reaction have shown a significant dependence 
on the solvent, initiator (base), and thiol used, and the reaction mechanism is dependent on these 




2.5. Solid-phase peptide synthesis 
Solid-phase peptide synthesis (SPPS) is a semi-automated technique commonly employed 
to synthesize peptides, typically less than 30 amino acids in length. Site-specific functionalization 
of a reactive handle occurs in one of two different ways, either using an amino acid mimic (Section 
2.5.1) within the peptide sequence or by installing a heterobifunctional linker (Section 2.5.2) 
bearing the reactive functional group of interest. 
 
2.5.1. Amino acid mimics 
A wide range of amino acid mimics are available with both azide and alkyne functional 
groups, and protected versions of these compounds (Figure 7) can be used to enable selective 
incorporation of the desired handle during SPPS.53  Peptides bearing both azide and terminal 
alkyne handles also present an attractive way to make cyclic peptides, and have literature 
precedence.54 This affords an ideal replacement for the disulfide bond commonly used for 
cyclization reactions, which is susceptible to oxidizing/reducing environments and disulfide 
exchange, as the triazole ring adds enhanced stability. Additionally, exploiting the Cu- and Ru-
catalyzed variants of the cycloaddition reaction can have a dramatic effect on activity by making 




Figure 7: Sample protected amino acids available for incorporation of azide- or alkyne-reactive handles during SPPS. 
 
2.5.2. Heterobifunctional linkers 
In the event that preservation of side chain binding interactions is required to maintain 
activity, heterobifunctional reagents can also be useful to install N-terminal linkers as the final step 
of SPPS.  Since these linkers do not contain a primary amine functionality, the need for protection 
and deprotection is eliminated. The heterobifunctional linker reacts as an amino acid during the 
peptide synthesis process, which would require a carboxylic acid functionality, in addition to the 
azide or alkyne functional group of interest (Figure 8). PEGylated forms of the heterobifunctional 
linkers are available in various lengths, which permits precise spacing of the reactive handle. 
Successful click conjugation using this approach has been used with a variety of different 
molecules,31, 56-57 and enables the selective orientation and spacing to the molecule of interest by 




Figure 8: Sample heterobifunctional linkers employed for the installation of a reactive handle. 
 
2.6. Metabolic labeling methods 
Installation of a reactive handle through metabolic labeling is becoming increasingly 
popular to provide a measure of metabolic activity, as modified biomolecules incorporate into 
biosynthetic pathways in the same manner as their unmodified counterparts. However, for 
biomolecules expressed in cell systems prior to isolation, this provides an attractive method for 




Figure 9: Sample functionalized amino acids for site specific incorporation of a reactive handle. 
 
2.6.1. Amino acid mimics 
Selective and reproducible modification of larger protein molecules has proved to be 
challenging with NHS ester or maleimide chemistries, since the surface-exposed lysine and 
cysteine residues targeted can be abundant on larger proteins. To circumnavigate this challenge, 
unnatural amino acids (UAAs) bearing reactive functionalities have literature precedence58-60 
(Figure 9) and are successfully incorporated into active protein synthesis with the addition of an 
engineered tRNA specific for the UAA. Not only does this permit selective incorporation of a 
reactive handle into the protein, it can also be used in conjunction with an azide- or alkyne-labeled 




Figure 10: Azide- and alkyne-modified sugars used for metabolic labeling of proteins which undergo post-
translational glycosylation. 
 
2.6.2. Post-translation modifications 
For proteins expressed in cell systems, exploiting post-translational glycosylation becomes 
another attractive approach for site-specific conjugation. Acetylated versions of modified sugars 
(Figure 10) added to the growth medium, and following internalization, non-specific proteases 
hydrolyze the acetate groups and release the sugar mimic bearing an azide or alkyne functional 
group. These sugars incorporate into glycosylated proteins, permitting subsequent conjugation 
either in vitro, or following protein isolation. For proteins which undergo post-translational 
lipidation or prenylation, alkyne-modified variants of fatty acids (Figure 11A) or isoprenoid 
precursors61 (Figure 11B) can incorporate into biosynthetic pathways in the same manner as their 
unmodified counterparts, enabling a method of site-specific incorporation of a reactive handle, or 
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to directly measure metabolic activity when combined with an azide- or alkyne- modified 
fluorophore. 
 
Figure 11: Alkyne-modified fatty acids and isoprenoids used for metabolic labeling of post-translational lipidation or 
prenylation. 
 
2.6.3. Nucleic acids and other anchors for live cell bioconjugation 
While primarily used for imaging applications, azide- and alkyne-modified nucleic acids 
(Figure 12A and B) and other membrane components (Figure 12C and D) have been used to install 
a reactive handle in actively synthesized DNA,62 RNA,63 or cell membrane components. Following 
installation of the reactive handle, conjugating molecules that enhance targeting, alter binding64 or 
expression, provide significant potential for therapeutic use. Additionally, when used in 
conjunction with a fluorescent probe bearing an azide or alkyne moiety, these molecules are useful 





Figure 12: Azide- and alkyne-modified chemical probes used for labeling. (A) DNA probes used for live cell labeling, 
(B) RNA probe used for live cell labeling, (C) phospholipid precursor used for labeling cell membranes, (D) 
cholesterol probe used for membrane incorporation. 
 
2.7. Payload molecules for modulating biomolecule function 
With the significant interest and development surrounding the azide-alkyne click reaction 
since its inception, a number of molecules have emerged in the literature which enable facile access 
to key functionalities (Figure 13). Most commonly, fluorescent tags installed on biomolecules 
permits visualization of a molecule of interest inside a cell, or for quantitation using techniques 
such as flow cytometry. Sivakumar et al. developed a pro-fluorescent coumarin molecule 
(Coumarin-N3, Figure 13A), having negligible fluorescence in the unconjugated form, and 
becoming fluorescent after the click reaction extends the conjugated system.65 This molecule has 




Figure 13: Sample payload molecules enabling facile access to added functionality. (A) Fluorophores spanning the 
spectral range, (B) radiolabels for incorporating a non-fluorescent tracer, (C) PEGylating reagents. 
A significant number of radiolabels (Figure 13B) have been described in the literature, enabling 
access to both targeted radiotherapy and in vivo visualization and quantitation techniques not 
possible with fluorescence labels, such as positron emission tomography (PET) and single photon 
emission computed tomography (SPECT).66 PEGylation reagents (Figure 13C) are also available 
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as a method to modify clearance or other pharmacokinetic parameters of a biomolecule, or to alter 
the biodistribution of a molecule by making significant changes to its molecular weight. 
 
2.8. Challenges associated with bioconjugates 
2.8.1. Synthetic and analytical considerations 
Bioconjugates are an exciting area that can exploit the benefits of multiple molecules with 
different properties, but their complexity often brings new challenges with respect to the synthesis 
and analysis of these constructs. Synthetic complications typically center on solubility or stability 
of the parent molecules or resulting conjugate, since proteins and other biomolecules are generally 
more sensitive than the payload to temperature and other environmental factors such as organic 
solvents, thereby limiting the approaches available to the traditional synthetic chemist. Analytical 
hurdles reside around heterogeneity, deconvolution of data and limited sample quantities due to 
high costs of proteins, which has led to the adaption of methods and techniques to comply with 
these demands.   
Solubility of the biomolecule and payload are required for the success of the conjugation 
reaction. However, payload molecules with minimal aqueous solubility will require assistance 
from an organic solvent to ensure the conjugation reaction can proceed. Dimethylsulfoxide 
(DMSO), N,N-dimethylformamide (DMF), and acetonitrile (MeCN) have seen use in these 
situations, removed effectively by dialysis or other size exclusion method after the completion of 
the reaction. Biomolecules with higher order structure can be conformationally altered in the 
presence of organic solvents, or have limited solubility as the organic concentration increases. 
Therefore, minimizing the overall organic solvent concentrations used in the reaction is often 
essential. NHS ester (Section 2.3) and related chemistries which target surface-exposed lysines or 
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other charged amino acids will have a greater impact on the overall solubility of the conjugate, 
since these amino acids assist in solubility of the biomolecule and will not remain charged 
following conjugation. To negate some of the deleterious effects of conjugation on solubility, 
linkers which have solubilizing moieties can either counteract or enhance solubility as desired in 
the conjugate.   
Importantly, a thorough understanding of the stability and degradation mechanisms of the 
parent molecules will guide the chemist in selecting appropriate reaction conditions while 
maintaining the integrity of the functional entities involved. These studies must assess both the 
physical and chemical stability of the molecules, since mechanisms leading to instabilities in small 
molecules are different than those seen for larger biomolecules. Proteins have a frequent 
propensity to aggregate in solution, a phenomenon which can be either reversible or irreversible. 
Aggregation can be especially problematic during synthesis, leading to precipitation and lower 
yields if not properly controlled. Aggregation during a chemical reaction can be limited by 
excipient addition, modifying the reaction environment (pH or ionic strength), decreasing reaction 
temperature, and limiting the amount of time the biomolecule is in solution. Any aggregates that 
form during the reaction should be separated from the product prior to final isolation, typically by 
filtration, centrifugation, or other size exclusion methods. Analytical techniques employed for 
studying aggregation in biomolecules include size exclusion chromatography (SEC), gel 
electrophoresis, or various spectrophotometric and light scattering particle sizing methods 
appropriate for the aggregate size involved. Liquid chromatography coupled with tandem mass 
spectrometry (LC/MS/MS), often proceeded by enzymatic digestion, is a powerful technique for 
understanding chemical degradation products in biomolecules. Small molecules are generally 
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more robust than biomolecules and the degradation products can be more easily understood using 
LC/MS and NMR techniques. 
Purification of bioconjugates constructed via the azide-alkyne cycloaddition reaction often 
require additional considerations. When employing the CuAAC variant, residual copper is 
undesirable in final products due to toxic and oxidative effects in living systems, but removal 
through common techniques appropriate for the compounds involved is generally adequate. For 
small molecules, copper binding resins such as Cuprisorb or chelators such as 
ethylenediaminetetraacetic acid (EDTA) are added following the reaction, which can also serve to 
quench the reaction.34 Peptides and proteins can be purified by chromatographic techniques like 
reverse phase high pressure liquid chromatography (HPLC), or through size exclusion methods 
such as dialysis where appropriate. Avoiding metal binding resins such as Cuprisorb due to a 
tendency to bind biomolecules is ideal. Following purification, inductively coupled plasma mass 
spectrometry (ICP-MS) is a useful technique for assessing the residual copper levels in the sample. 
Limiting side reactions with amino acid residues of biomolecules is a necessity to maintain 
activity in the final conjugate. CuAAC reactions employing the common Cu2+ and sodium 
ascorbate catalyst system (forming the corresponding dehydroascorbate byproduct) are known to 
lead to the formation of reactive oxygen species, which can degrade certain amino acids including 
histidine, arginine, cysteine and methionine.67 Cu-chelating ligands such as THPTA or TBTA can 
assist in limiting degradation, and the addition of reagents such as aminoguanidine, which act as a 
side chain surrogate for aminoguanidine, can also limit chemical degradation of the biomolecule. 
Cyclooctyne compounds are known to react with reduced cysteine residues through a thiol-yne 
mechanism, although this has been shown to be mitigated through pre-incubation with 
iodoacetamide, which is compatible with the subsequent SPAAC conjugation reaction.68 
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The AAC reaction carries significant precedence in the polymers field with respect to 
hydrogels.69-72 An added complication of bioconjugation to polymers is the tendency for intra- or 
inter-molecular entanglement, limiting the accessibility to reactive sites. Reduction of this 
phenomenon can occur through the addition of organic solvents known to denature the polymer,34 
addition of heat to induce thermal unfolding, or altering pH or ionic environment to disrupt specific 
interactions causing entanglement.73 In other cases, limited reactive site availability is due to the 
viscosity of high MW polymers, requiring more dilute reaction conditions. In general, conjugation 
efficiency will decrease as molecular weight increases due to reduced collisions with appropriate 
geometry and sufficient energy to react, especially in polymers such as hyaluronic acid which are 
self-associating or have secondary structure.74 
 
2.8.2. Biological consequences of solubility 
Solubility plays an important role in many physiological processes from biodistribution 
and clearance to immune recognition and response. Insoluble antigens are often processed by 
macrophages, while dendritic cells tend to process soluble materials.1 Therefore, modification of 
the native biomolecule’s solubility through conjugation can perturb native function, altering 
recognition, trafficking or uptake events. An understanding of aggregation propensity, with the 
associated decrease in solubility, is of critical importance in protein therapeutics, since aggregated 
proteins have the potential to induce an undesired immune response and lead to potentially serious 
adverse events for the patient.75 In 2014, the FDA issued guidance on immunogenicity assessment 
as a key parameter in the development of therapeutic protein products. Recent studies have also 
shown the impact of immunogenicity through the formation of anti-drug antibodies upon repeat 
administration of biologic treatments such as rituximab.76-77 
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In the context of antibody-drug conjugates (ADCs), most drugs conjugated to the antibody 
are relatively hydrophobic and have minimal aqueous solubility, while the antibody has sufficient 
aqueous solubility. Therefore, the resulting conjugate generally has intermediate solubility, often 
proportional to the molecular weight contribution of the parent compounds to the overall 
conjugate. This can be of significant benefit for the drug molecule, since hydrophobic drug 
molecules which typically enter cells via passive diffusion can exploit the active transport 
mechanisms used to internalize the antibody, but can also be detrimental to the pharmacokinetic 
properties of the antibody. Additionally, studies have shown high drug-to-antibody ratios (DAR) 
impact both potency and clearance, although modulated through varying the hydrophilic or 
hydrophobic nature of the linker.78-79   
Efflux pumps such as the multidrug resistance (MDR) proteins target molecules for export, 
and are more effective at transporting hydrophobic molecules than hydrophilic molecules. A 
correlation between MDR expression and poor clinical response has been documented,80 which is 
an important observation and should be taken into consideration in bioconjugate design. Studies 
have shown that trastuzumab linked to the maytansinoid DM1 via a hydrophilic PEGylated linker 
were more potent towards MDR+ cells than those containing the more hydrophobic N-
succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker,81 highlighting the 
important impact of solubility on therapeutic function. 
 
2.8.3. Linker stability 
Another critical component to a bioconjugate is the design of the linker, since this can also 
have a dramatic impact on the efficacy of the bioconjugate. Both cleavable and non-cleavable 
linker strategies have been used in the ADC field as well as in other bioconjugates. Cleavable 
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linkers typically exploit environmental factors present in the cellular location where payload 
release is desired, involving either pH, oxidizing/reducing conditions, or the presence of a relevant 
enzyme. While this approach may be attractive in theory, and may be necessary for successful 
action of the payload, the mechanisms that release the payload may not be specific to only the 
desired target location. For example, pH sensitive linkers present in the bioconjugate can encounter 
acidic microenvironments during trafficking to the target location, and could release the payload 
in unintended locations throughout the body, yielding adverse side effects for the patient. 
The ‘bystander effect’ in ADCs that specifically target solid tumors is documented, and is 
known to express surface antigens in a heterogeneous manner. In these cases, an understanding of 
the drug release mechanism is essential, since treatment with an ADC may not be sufficient to 
eliminate all of the solid tumor, given that cell populations with limited surface antigen expression 
will see limited targeting by the ADC. Brentuximab vedotin utilizes a cathepsin cleavable linker 
to conjugate the toxin monomethyl auristatin E (MMAE) to the antibody, releasing the toxin in a 
neutral form capable of crossing biological membranes of adjacent tumor cells not initially targeted 
by the ADC. When the structural analogue, monomethyl auristatin F (MMAF), is conjugated to an 
antibody and released in active form as a charged species, diffusion across membranes is limited, 
and the bystander effect is reduced. Cleavable linkers, present in trastuzumab duocarmazine,82 are 
more prone to the bystander effect83 than those containing non-cleavable thioether linkages, such 
as trastuzumab emtansine. This underlines the importance of a thorough understanding of the 
stability of the linker and payload release, since the bystander effect provides an added mechanism 




2.8.4. Conjugation site and loading 
Inactivation of the small molecule can occur through structural modifications that impart 
improper active site geometry. When available, crystal structures or models of drug molecules 
bound to their target can assist in selection of potential linkage sites on the active compound.84-85 
Similarly, the site of conjugation to the biomolecule is critical to maintain activity of the conjugate. 
Modern ADCs employ site specific approaches to conjugate drugs in the Fc region of antibodies 
to prevent inhibition of binding between the antibody Fab region and the cell surface antigen, 
thereby increasing therapeutic activity.86 The construction of reproducible and homogeneous 
bioconjugates has improved in recent years with the advent of unnatural amino acids   (Figure 9) 
and engineered cysteines.19 
Multiple groups have demonstrated the impact of DAR on efficacy, and commercially-
approved ADCs are present as mixtures of regioisomers, each having different safety and efficacy 
profiles.78 DAR 0 species are particularly unfavorable due to competitive binding with antigenic 
receptors without delivering the warhead, leading to an overall decreased potency of the 
therapeutic. Most ADCs target a DAR of 3-4, with higher values altering clearance and 
biodistribution without a continued increase in activity,78 resulting in a higher toxicity and lower 
therapeutic index.87 Supporting these findings is the observation of increased liver accumulation 
with high DAR species, leading to faster clearance rates.78 Physical instabilities with high DAR 
species is also noted, leading to increased aggregation with elevated DAR.88 
Bioconjugates involving two larger molecules such as polymers and proteins have to 
consider the impact of the size of the resulting conjugate, including hydrodynamic radius and 
structure. While two independent molecules may localize specifically in vivo, the modification in 
size can have implications on trafficking,89 clearance, immune response,29 and cellular uptake.90 
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This effect of size on biodistribution is a phenomenon also seen in the nanoparticle field,91 and is 
an important characteristic to consider when designing bioconjugates and must be adequately 
characterized using size-appropriate analytical methods.  
 
2.9. Conclusions and Future Directions 
Bioconjugates represent a rapidly growing field by creating hybrid molecules that exploit 
the advantages of multiple molecular entities. As the field continues to emerge, an increased 
understanding of the impact of key parameters such as solubility, stability, and size have on the 
pharmacokinetics, pharmacodynamics, and safety profile are of paramount importance. Efforts to 
limit therapeutic heterogeneity and increase the specificity of these complex molecules have seen 
improvements in patient outcomes and will only continue to increase as development progresses. 
Given the significant clinical advancement of ADCs, a broad expansion of the toolbox of 
available linkers, antibodies and warheads will further the applicability of this approach. Applying 
the AAC reaction to a large set of functionalized molecules has enabled a combinatorial approach 
to high-throughput conjugate generation,92-93 which could be optimized over time once lead 
candidate have been identified. An additional benefit of toolbox development is the ability to 
overcome resistance by altering one of the components which may be targeted by mechanisms 
such as efflux pumps, altered expression of pro-apoptotic proteins, or downregulation of cell-
surface antigens.19 Studies have shown that overcoming resistance to a warhead present on an 
ADC is possible by altering the payload molecule,94 highlighting the critical need for a wide array 
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CHAPTER 3: ANTIGEN-DRUG CONJUGATES AS A NOVEL THERAPEUTIC CLASS FOR ANTIGEN-
SPECIFIC AUTOIMMUNE DISORDERS 
3.1. Introduction 
The adaptive immune response is dependent on recognition of target antigens, and 
autoimmune diseases occur when the body fails to maintain tolerance toward self-antigens.1 These 
self-antigens can be present in a number of host tissues in various organs, leading to diseases such 
as multiple sclerosis (MS).2 MS is the most common cause of neurological disability in young 
adults, affecting approximately 2.5 million patients worldwide,3 and is highly variable in terms of 
clinical manifestation.4 While the mechanism has not been fully elucidated, the prevailing theory 
is that proteins composing the myelin sheath coating neurons of the central nervous system (CNS), 
such as proteolipid protein (PLP) and myelin basic protein (MBP), trigger recruitment of myelin-
specific CD4+ T cells, resulting in inflammation leading to demyelination.95     
The treatment landscape for MS is expanding as our understanding of pathogenesis 
continues to evolve. Corticosteroids have been a cornerstone for MS therapy,12 acting through 
downregulation of pro-inflammatory cytokine production, inhibiting antibody production, or 
reducing BBB permeability.96 IFN-β reduces T-cell activation and proliferation, in addition to 
downregulating the cell surface receptors involved in antigen presentation.96 Glatiramir acetate is 
thought to function by blocking lymphocyte sensitization to MBP via competitive inhibition of 
antigen presentation.13 Newer monoclonal antibody therapies alleviate inflammation in the CNS 
through a variety of mechanisms, including altered immune cell trafficking (natalizumab), B-cell 
depletion (rituximab and alemtuzumab), or T-cell expansion (daclizumab).96 Importantly, all of 
these treatments lead to undesired side effects, can be minimally efficacious, and modify normal 
immune system functions. Typically, these effects are a result of a lack of therapeutic specificity, 
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and here, we present antigen-drug conjugates (AgDCs) as an alternative to these approaches with 
the potential to mitigate the detriments of these treatments to increase both safety and efficacy. 
AgDCs are a combination of the two general approaches to combat autoimmunity – 
immunomodulatory agents and hyposensitization therapy. While hyposensitization therapies have 
shown minimal efficacy in clinical studies for autoimmune diseases, they provide the specificity 
necessary to reverse an immune response toward a particular antigen, and have been effective at 
inducing tolerance towards allergens. Immunomodulatory agents show greater efficacy in 
autoimmune diseases, but suffer from systemic action and subsequent global immunosuppression, 
which can be problematic in immunocompromised patient populations by increasing the 
vulnerability to opportunistic infections. Through conjugation of the antigen and 
immunomodulator, the antigen is able to function as a directing agent to target the 
immunomodulator to offending immune cell populations and limit off target effects seen with 
treatment by the immunomodulator alone. An analogous approach has seen significant clinical 
success in recent years in the field of immunooncology with the development of antibody-drug 
conjugates (ADCs). The inverse concept of AgDCs has yet to be attempted for autoimmune 
indications. 
MS is a neurodegenerative disease unique to humans, but can be effectively mimicked in 
the murine model of experimental autoimmune encephalomyelitis (EAE).8 The relapsing-remitting 
EAE model exhibits CD4+ T cell-mediated disease, leading to primary demyelination of the axonal 
tracks in the CNS and subsequent progressive paralysis of the limbs.7 Disease induction occurs 
through an adjuvanted ‘vaccine’ containing the antigenic epitope, PLP139-151, injected 
subcutaneously, and mimics the clinical and histopathological similarities seen with relapsing-
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remitting multiple sclerosis (RRMS) in humans.2 EAE is considered to be the best defined 
preclinical model for organ-specific autoimmunity mediated by a Th1/Th17-driven response.2 
 
3.2. Materials and Methods 
Dexamethasone, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), and sodium 
ascorbate (NaAsc) were purchased from Sigma-Aldrich (St. Louis, MO). Copper(II) sulfate 
pentahydrate (CuSO4 • 5H2O) was purchased from Acros Organics (Geel, Belgium). 2,5-
dioxopyrrolidin-1-yl 2-azidoacetate, DBCO-PEG4-Maleimide, DBCO-NH2, and MMAE-DBCO 
were purchased from Clickchemistrytools, LLC (Scottsdale, AZ).  Doxorubicin hydrochloride was 
purchased from LC Laboratories (Woburn, MA). Mertansine (DM1) was purchased from 
Carbosynth Limited (Berkshire, UK).  All other chemicals and reagents were analytical grade and 
were used as received without further purification. 
The peptides PLP139-151-Alk and PLP139-151-N3 have been synthesized in our laboratory via 
solid phase peptide synthesis on a Wang resin, but larger quantities of each peptide were obtained 
from Biomatik Corporation (Wilmington, DE). In each case, the linker 3-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)propanoic acid was purchased from PurePEG, LLC (San Diego, CA) 




3.2.1. Synthetic procedures 
3.2.1.1. Synthesis of DBCO-functionalized Rhodamine B (Rhod-DBCO) 
 
Figure 14: Reaction scheme for the synthesis of Rhod-DBCO. 
The starting Rhodamine B NHS Ester was synthesized from the parent Rhodamine B dye, 
according to a literature procedure.97 DBCO-PEG4-NH2 (29.6 μmol) in 2 mL of DMSO was added 
to a solution of Rhodamine B NHS Ester (37.0 μmol, 1.2 eq.) in 2 mL of DMSO. The solution was 
allowed to stir at room temperature while protected from light, while periodically removing an 
aliquot to monitor reaction progress by analytical HPLC. After 2 hours, the solution was purified 
by preparative HPLC on a Waters XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column using a 
gradient of MeCN in H2O (constant 0.05% TFA). The isolated fractions were evaporated under 
reduced pressure to remove residual MeCN, then frozen at -20°C and lyophilized to yield a purple 
powder. Expected [M]+ = 1099.4845 Da, [M+H]2+ = 550.2459 Da; Observed [M]+ = 1099.4762 




3.2.1.2. Synthesis of azide-functionalized dexamethasone (Dex-N3) 
 
Figure 15: Reaction scheme for the synthesis of Dex-N3. 
Dexamethasone was added to a flame dried 250mL round bottom flask with a stir bar and 
septa. Anhydrous MeCN was added under nitrogen, then DIPEA via glass syringe. The flask was 
stirred for 10 min before azidoacetic acid NHS ester was added as a powder. The reaction mixture 
was stirred overnight at room temperature before being analyzed by HPLC. Additional equimolar 
aliquots of azidoacetic acid NHS ester were added, followed by stirring for 2 hours at room 
temperature and analyzing by HPLC, until no additional benefit was observed. The crude reaction 
mixture was evaporated under reduced pressure, then dissolved in 4:6 MeCN:H2O and purified by 
prep HPLC. The resulting column fractions were evaporated under reduced pressure to yield the 
final product as a white powder. 1H NMR (500 MHz, DMSO-d6) δ 7.30 (d, J = 10.2 Hz, 1H), 6.23 
(dd, J = 10.1, 1.9 Hz, 1H), 6.01 (t, J = 1.7 Hz, 1H), 5.45 (dd, J = 5.0, 1.4 Hz, 1H), 5.23 (s, 1H), 
5.17 (d, J = 17.5 Hz, 1H), 4.90 (d, J = 17.6 Hz, 1H), 4.32 – 4.19 (m, 2H), 4.19 – 4.11 (m, 1H), 2.88 
(dqd, J = 11.5, 7.2, 4.1 Hz, 1H), 2.62 (tdd, J = 13.6, 6.0, 1.7 Hz, 1H), 2.44 – 2.32 (m, 1H), 2.35 – 
2.28 (m, 1H), 2.22 – 2.05 (m, 3H), 1.77 (dt, J = 11.2, 5.2 Hz, 1H), 1.70 – 1.58 (m, 1H), 1.56 (dd, 
J = 13.8, 2.0 Hz, 1H), 1.49 (s, 3H), 1.35 (qd, J = 12.9, 5.0 Hz, 1H), 1.08 (ddd, J = 12.1, 8.2, 4.1 
Hz, 1H), 0.89 (s, 3H), 0.80 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 204.36, 185.30, 
168.28, 167.10, 152.77, 129.03, 124.12, 102.00, 100.61, 90.52, 70.63, 70.34, 69.00, 49.34, 48.09, 
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48.05, 47.87, 43.33, 35.69, 35.53, 33.67, 33.51, 31.92, 30.28, 27.32, 23.03, 22.98, 16.31, 15.15, 
1.19. Expected [M+H]+ = 476.2191 Da; Observed [M+H]+ = 476.2067 Da. 
 
3.2.1.3. Synthesis of azide-functionalized doxorubicin (Dox-N3) 
 
Figure 16: Reaction scheme for the synthesis of Dox-N3. 
To a flame dried 20 mL scintillation vial (protected from light) with stir bar was added 
doxorubicin hydrochloride, followed by anhydrous DMSO. Once dissolved, DIPEA was added 
via syringe, then stirred for 5 min, followed by azidoacetic acid NHS ester as a powder. The 
solution was stirred overnight at room temperature, then analyzed by analytical HPLC to determine 
the extent of reaction. The crude mixture was purified by prep HPLC, and the column fractions 
were evaporated under reduced pressure to yield a red powder. 1H NMR (500 MHz, DMSO-d6) δ 
14.02 (s, 1H), 13.26 (s, 1H), 7.94 – 7.85 (m, 3H), 7.67 – 7.60 (m, 1H), 5.23 (d, J = 3.5 Hz, 1H), 
4.93 (dd, J = 5.6, 3.3 Hz, 1H), 4.58 (s, 2H), 4.19 (dt, J = 7.3, 6.0 Hz, 2H), 4.01 (ddd, J = 9.7, 4.6, 
2.3 Hz, 1H), 3.97 (s, 4H), 3.76 (d, J = 4.8 Hz, 2H), 3.48 – 3.39 (m, 2H), 3.03 – 2.88 (m, 2H), 2.24 
– 2.16 (m, 1H), 2.10 (dd, J = 14.3, 5.7 Hz, 1H), 1.84 (td, J = 12.9, 3.8 Hz, 1H), 1.45 (dd, J = 12.5, 
4.6 Hz, 1H), 1.13 (d, J = 6.5 Hz, 3H), 1.05 (t, J = 7.0 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 
213.91, 186.57, 186.48, 166.61, 160.79, 156.12, 154.51, 136.24, 135.52, 134.69, 134.10, 120.01, 
119.75, 119.01, 110.80, 110.67, 100.31, 100.25, 74.94, 70.02, 69.98, 67.85, 66.63, 66.58, 63.71, 
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56.63, 56.57, 50.58, 50.53, 50.48, 45.37, 45.32, 36.65, 32.06, 29.65, 17.02, 17.00. Expected 
[M+Na]+ = 649.1752 Da; Observed [M+Na]+ = 649.1498 Da. 
 
3.2.1.4. Synthesis of DBCO-functionalized DM1 (DM1-DBCO) 
 
Figure 17: Reaction scheme for the synthesis of DM1-DBCO. 
DM1 (33.9 μmol) in 2.5 mL of DMSO was added to DBCO-PEG4-Maleimide (36.35 μmol, 
1.07 eq.) in 2.5 mL of DMSO. The solution was stirred at room temperature for 1 hour before an 
aliquot was removed for reaction monitoring by analytical HPLC. After 2 hours, the reaction was 
purified by preparative HPLC on a Waters XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column 
using a gradient of MeCN in H2O (constant 0.05% TFA). The isolated fractions were evaporated 
under reduced pressure to remove residual MeCN, then frozen at -20°C and lyophilized to yield a 
white powder. Expected [M+H]+ = 1563.5713 Da; Observed [M+H]+ = 1563.5530 Da. 
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3.2.1.5. Synthesis of PLP139-151-Rhodamine B (PLP139-151-Rhod) 
 
Figure 18: Reaction scheme for the synthesis of PLP139-151-Rhod. 
PLP139-151-N3 (18.3 μmol) in 3.0 mL of 20 mM phosphate buffer (pH 7.0) was added to 
Rhod-DBCO (18.2 μmol, 1.0 eq.) in 3.0 mL of DMSO. The solution was allowed to stir at room 
temperature for 1 hour before an aliquot was removed for reaction monitoring by analytical HPLC. 
After 2 hours, the reaction was purified by preparative HPLC on a Waters XBridge BEH C18, 5 
μm, 130 Å, 19x250 mm column using a gradient of MeCN in H2O (constant 0.05% TFA). The 
isolated fractions were evaporated under reduced pressure to remove residual MeCN, then frozen 
at -20°C and lyophilized to yield a purple powder. Expected [M+2H]3+ = 950.7992 Da, [M+3H]4+ 
= 713.3512 Da; Observed, [M+2H]3+ = 950.8094 Da, [M+3H]4+ = 713.3638 Da. 
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3.2.1.6. Synthesis of PLP139-151-Doxorubicin (PLP139-151-Dox) 
 
Figure 19: Reaction scheme for the synthesis of PLP139-151-Dox. 
To a solution of PLP139-151-Alk (12.5 μmol) in 5 mL deionized H2O was added Dox-N3 
(19.2 μmol, 1.53 eq.) in 1 mL EtOH, while protecting the reaction from light. 225 μL of a premixed 
solution of CuSO4•5H2O (1.5 μmol) and THPTA (7.5 μmol) in deionized H2O was added to the 
reaction mixture, followed by 320 μL of NaAsc (32.3 μmol) in deionized H2O. The reaction was 
allowed to stir at room temperature for 1 hour before an aliquot was removed for analytical HPLC 
to monitor reaction progress. After 2 hours, the reaction mixture was purified by preparative HPLC 
on a Waters XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column using a gradient of MeCN in 
H2O (constant 0.05% TFA). The isolated fractions were evaporated under reduced pressure to 
remove residual MeCN, then frozen at -20°C and lyophilized to yield a red powder. Expected 
[M+2H]2+ = 1115.0095 Da, [M+3H]3+ = 743.6754 Da; Observed [M+2H]2+ = 1115.0045 Da, 




3.2.1.7. Synthesis of PLP139-151-Dexamethasone (PLP139-151-Dex) 
 
Figure 20: Reaction scheme for the synthesis of PLP139-151-Dex. 
To a solution of PLP139-151-Alk (93.6 μmol) in 120 mL deionized H2O was added Dex-N3 
(189.4 μmol, 2.02 eq.) in 12 mL EtOH. 5.7 mL of a premixed solution of CuSO4•5H2O (38.1 μmol) 
and THPTA (189.8 μmol) in deionized H2O was added to the reaction mixture, followed by 7.2 
mL of NaAsc (726.9 μmol) in deionized H2O. The reaction was allowed to stir at room temperature 
for 1 hour before an aliquot was removed for analytical HPLC to monitor reaction progress. After 
3 hours, the reaction mixture was concentrated under reduced pressure, and purified by preparative 
HPLC on a Waters XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column using a gradient of MeCN 
in H2O (constant 0.05% TFA). The isolated fractions were evaporated under reduced pressure to 
remove residual MeCN, then frozen at -20°C and lyophilized to yield a white powder. Expected 
[M+2H]2+ = 1039.5224 Da, [M+3H]3+ = 693.3507 Da; Observed [M+2H]2+ = 1039.5145 Da, 




3.2.1.8. Synthesis of PLP139-151-Mertansine (PLP139-151-DM1) 
 
Figure 21: Reaction scheme for the synthesis of PLP139-151-DM1. 
DM1-DBCO (6.4 μmol) in 2 mL of DMSO was added to PLP139-151-N3 (6.9 μmol, 1.07 
eq.) in 2 mL of 20 mM phosphate buffer (pH 7.0). The solution was stirred at room temperature 
for 1 hour before an aliquot was removed for reaction monitoring by analytical HPLC. After 2 
hours, the reaction was purified by preparative HPLC on a Waters XBridge BEH C18, 5 μm, 130 
Å, 19x250 mm column using a gradient of MeCN in H2O (constant 0.05% TFA). The isolated 
fractions were evaporated under reduced pressure to remove residual MeCN, then frozen at -20°C 
and lyophilized to yield a white powder. Expected [M+3H]3+ = 1105.4948 Da; Observed [M+3H]3+ 




3.2.1.9. Synthesis of PLP139-151-Monomethyl auristatin E (PLP139-151-MMAE) 
 
Figure 22: Reaction scheme for the synthesis of PLP139-151-MMAE. 
MMAE-DBCO (3.0 μmol) in 1 mL of DMSO was added to PLP139-151-N3 (3.0 μmol, 1.0 
eq.) in 1 mL of 20 mM phosphate buffer (pH 7.0). The solution was stirred at room temperature 
for 1 hour before an aliquot was removed for reaction monitoring by analytical HPLC. After 2 
hours, the reaction was purified by preparative HPLC on a Waters XBridge BEH C18, 5 μm, 130 
Å, 19x250 mm column using a gradient of MeCN in H2O (constant 0.05% TFA). The isolated 
fractions were evaporated under reduced pressure to remove residual MeCN, then frozen at -20°C 
and lyophilized to yield a white powder. Expected [M+3H]3+ = 1133.9656 Da, [M+4H]4+ = 




3.2.2. Analytical characterization 
All HPLC chromatographic analysis was conducted with a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For RP-HPLC, 
general chromatographic conditions employed a linear elution gradient from 5-95% acetonitrile in 
water (constant 0.05% trifluoroacetic acid) over 50 min, on a Waters XBridge BEH C18, 3.5 μm, 
130 Å stationary phase (4.6 x 150 mm), with a 1.0 mL/min flow rate and a 35°C column 
temperature. For semi-preparative HPLC, a linear elution gradient of acetonitrile in water (constant 
0.05% trifluoroacetic acid) over 20 min, on a Waters XBridge BEH C18, 5 μm, 130 Å stationary 
phase (19 x 250 mm), with a 14.0 mL/min flow rate. Gradients were optimized for each run using 
the identical stationary phase in a 4.6 x 250 mm configuration. 
LC/MS sample analysis was performed with a Waters Xevo G2, employing linear elution 
gradients of 15-100% acetonitrile in water (constant 0.1% formic acid) over 45 min, on a Waters 
XBridge BEH C18, 1.7 μm, 130 Å stationary phase (0.075 x 250 mm), with a 0.5 μL/min flow rate 
and 50°C column temperature. Electrospray ionization, operating in the positive mode (ESI+), was 
used as the ionization source with a QTof mass analyzer used for detection.   
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe. All samples were dissolved in 650 μL of D2O or DMSO-d6. 
Data processing was performed using MestReNova 11.0 (Santiago de Compostela, Spain). 
 
3.2.3. Drug release and stability studies 
Release and stability studies were conducted via HPLC with UV detection by dissolving 
the compound of interest in buffers relevant for in vivo administration of analytical sample 
analysis, typically deionized H2O, saline, phosphate buffered saline (pH 7.4), 10 mM phosphate 
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(pH 7.4) or 10 mM acetate (pH 5.5) and evaluating the release at temperatures and times relevant 
to the particular study. For compounds such as PLP139-151-Dex where the released drug has a 
significantly different extinction coefficient at the detection wavelength, drug release was 
measured using a linear calibration curve. 
 
3.2.4. Determination of IC50 in EAE splenocytes 
Splenocytes were harvested from EAE mice on day 12 (peak of disease), which received 
no previous treatment, and cultured in the specified treatment at the designated concentrations for 
120 hrs before being subjected to resazurin (N = 6 spleens/group). All data points were normalized 
to the mean resazurin response generated from untreated splenocytes. 
 
3.2.5. In vivo studies in EAE mice 
In vivo studies were carried out with 4-6 week old SJL/J (H-2) female mice. Mice were 
housed under specified, pathogen-free conditions and all experiments were approved by the 
University of Kansas Institutional Animal Care and Use Committee. On day 0, all mice were 
induced with EAE to mimic the effects of multiple sclerosis, by 4 subcutaneous injections of an 
emulsion containing PLP and complete Freund’s adjuvant (CFA) which contains killed 
Mycobacterium tuberculosis capsid. Four subcutaneous injections were administered (N = 5 
mice/group) above each shoulder blade (200 μL total). Pertussis toxin (100 ng in 100 μL) was 
injected intraperitoneally on day 0 and day 2 post-immunization. 100 μL treatments were 
administered subcutaneously on days 4, 7, and 10, with 400 nmol (Dex basis), with the control 
group receiving PBS. All mice were weighed and scored daily on a scale of 0-5, with 5 indicating 
highest disease severity. All mice were euthanized on day 25. 
49 
 
3.3. Results and Discussion 
3.3.1. Therapeutic design, rationale, and drug selection 
AgDCs were designed to utilize antigen as a guide molecule for delivering a drug to cells 
contributing to autoimmunity. Active drug molecules were selected based on mechanism of action, 
potency, appropriate target location, and the presence of an available synthetic handle. Whenever 
possible, available crystal structures or other structural data were included in synthetic design to 
avoid inactivating the drug molecule due to inappropriate active site geometry or pharmacophore 
availability following conjugation. Two primary drug classes were selected in these studies, 
depending on the desired therapeutic outcome. Upon uptake into diseased cell populations, Dex is 
expected to mitigate inflammation by suppressing the normal immune response induced by PLP. 
Alternatively, potent cytotoxins such as mertansine (DM1), monomethyl auristatin E (MMAE), or 
doxorubicin (Dox) targeting the same cell populations would induce apoptosis and prevent further 
immune cell activation. All three of the cytotoxic compounds have been used clinically as ADC 
payloads,19 and DM1 and MMAE are conjugated to directing antibodies in the commercially-
approved therapeutics trastuzumab emtansine (T-DM1) and brentuximab vedotin (B-MMAE), 
respectively. All of these compounds, either in their parent form or commercially available 
derivative, contain reactive functionalities suitable for conjugation. Additionally, a fluorescently 
labeled conjugate based on the fluorophore rhodamine B was synthesized to elucidate antigen 
binding kinetics and specificity in future studies. 
The encephalitogenic peptide selected as the targeting moiety is a portion of the 
intracellular loop98 of the full-length proteolipid protein, PLP139-151. Previous studies have shown 
the impact of PLP139-151 sequence variability on binding affinity,
99 highlighting the necessity to 
maintain the native sequence unchanged. Therefore, employing traditional synthetic methods 
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targeting side chain residues of the native sequence will likely alter conjugate binding and/or 
uptake. To circumnavigate these potential deleterious effects, all modifications to the targeting 
antigen occurred through the N-terminal amino acid, functionalized with heterobifunctional 
linkers as the final step of solid-phase peptide synthesis prior to cleavage from the resin.    
Linker length, flexibility, and stability were key AgDC design considerations. Short linkers 
could potentially alter binding, while long linkers could affect mechanisms of internalization. For 
hydrophobic drug molecules, PEGylated or sulfonated linkers were used to increase aqueous 
solubility and compatibility with downstream reactions. In T-DM1, the payload is linked via a 
non-cleavable thioether bond, and preclinical studies employing disulfide linkages showed similar 
efficacy. To decrease the possibility of off target effects from cleavage of the drug following 
administration but prior to internalization, a thioether linker was selected. B-MMAE employs a 
valine-citrulline linker, which is cleaved by cathepsin B post-internalization, but previous studies 
have shown conjugates formed using non-cleavable maleimidocaproyl linkers also maintain 
activity following lysosomal catabolism.100 Doxorubicin immunoconjugates have typically been 
constructed with acid labile hydrazone linkages101 or through carbamate formation or amidation 
of the daunosamine ring,102-103 and a stable amide bond was selected here to limit off-target 
toxicity. 
 
3.3.2. Synthetic strategy and optimization 
The overarching strategy was the development of a modular antigen and payload library 
that would enable the rapid and efficient synthesis of therapeutic or diagnostic conjugates (Figure 




Figure 23: Compound library employed for AgDCs. A) General reaction schemes for the copper-catalyzed azide-
alkyne cycloaddition (CuAAC) and strain-promoted azide-alkyne cycloaddition (SPAAC) reactions used for 
conjugation. B) Functionalized antigenic carrier peptides. C) Functionalized ‘payload’ molecules. 
the copper-catalyzed azide-alkyne cycloaddition (CuAAC), and the strain-promoted azide-alkyne 
cycloaddition (SPAAC). Both reactions carry significant precedence, with a wealth of 
development and optimization studies available in the primary literature.32-34, 44 There is also 
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significant precedence with respect to application of these chemistries in the field of 
bioconjugation,18, 33, 92, 104 making construction of the payload library a less difficult endeavor.   
Azide- and alkyne-functionalization of payload molecules generally involved N-
hydroxysuccinimidyl activated esters (NHS esters) with a corresponding nucleophilic group on the 
payload, or Michael additions to electrophilic centers via maleimide chemistry. Both types of 
chemistry are routinely employed in bioconjugation applications, targeting side chains of lysine or 
cysteine residues, respectively. Due to the biocompatibility of this approach, minimal side 
reactions are observed, making the synthesis and purification more favorable. Similarly, peptide 
antigens employed the compounds 4-pentynoic acid and COOH-PEG3-N3 for alkyne- and azide-
functionalization, respectively. 
One additional strength to the CuAAC and SPAAC conjugation chemistries is the 
relatively high yields, fast reaction times, and mild reaction conditions. Optimization of 
conjugation conditions generally began in aqueous media, with the exception of those conjugates 
involving less soluble payloads which required the assistance of organic solvents such as DMSO, 
DMF, or EtOH. Evaluation of reaction conditions occurred on the sub-milligram scale with the 
simultaneous development of HPLC methods employed for the downstream purification and 
analysis. In general, higher initial success was observed with SPAAC conjugates, yielding suitable 
reaction conditions with minimal development due to the lack of necessary catalyst, ligand, and 
reducing agent. As the initial molecular weights of the antigen and payloads were on the same 
order of magnitude, a 1:1 stoichiometric ratio was sufficient to produce high yields of the conjugate 
(>80%), which could be easily isolated from residual starting materials by preparative HPLC. 
Conjugates constructed with CuAAC chemistry typically involved more development with respect 
to reactant and catalyst concentrations, in addition to stoichiometric excess of the payload relative 
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to the antigen. In all cases, the amphiphilic nature of the conjugates made HPLC method 
development relatively straightforward, with significant retention differences between the 
hydrophilic peptide and hydrophobic drug often leaving the conjugate with an intermediate 
retention time compared to the parent compounds. 
 
3.3.3. Characterization of conjugates and intermediates 
The payload molecules and conjugates described were characterized by traditional 
chemical methods, including NMR, HPLC, LC/MS, and other spectroscopic means to confirm the 
structure of the entity. As opposed to ADCs which present additional analytical challenges due to 
molecular heterogeneity, AgDCs synthesized here were a more defined molecular species with 
high purity. HPLC analysis of the conjugates with UV/Vis detection provides typical purity values 
in excess of 93-95% following purification (Figure 24, Figure 25, and Figure 26), with impurities 
generally having retention times close to the parent conjugate. A similar analysis by UPLC with 
detection by mass spectrometry corroborated these results, showing multiple charge states of the 
compound indicative of attachment of the peptide antigen. Analysis of NMR proved to be more 
suitable for structural confirmation of small molecule payloads. However, one added benefit to the 
CuAAC chemistry when installing alkyne linkers on the peptide was the presence of a distinct 
resonance in 1H/13C heteronuclear single quantum coherence (HSQC) NMR, corresponding to the 
terminal alkyne correlation (δ(1H) ≈ 2.3 ppm, δ(13C) ≈ 70 ppm), which is present in a unique 
chemical environment and well separated from other signals. After conjugation, this resonance 
undergoes a significant downfield shift upon incorporation as part of the conjugated triazole ring 
system (Figure 27). 
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Figure 24: Representative analytical HPLC chromatogram showing the starting materials, PLP-Alk, and Dex-N3, 
along with the purified reaction product, PLP-Dex. 
 
 
Figure 25: Analytical HPLC chromatograms of the starting materials and the purified reaction product, PLP139-151-





Figure 26: Analytical HPLC chromatograms of the starting materials and the purified reaction product, PLP139-151-
DM1.  The presence of a split peak in the DM1-DBCO reaction product suggests the presence of a chiral center, and 
the heterogeneity of the PLP139-151-DM1 peak indicates the formation of regioisomers produced from each of the 
starting stereoisomers. 
One additional advantage of conjugating hydrophobic drug molecules to hydrophilic 
peptides was the impact on aqueous solubility. The PLP139-151 peptide is soluble in excess of 60 
mg/mL, providing a significant enhancement in drug solubility of the resulting amphiphilic 
conjugates. A noteworthy observation from HPLC analysis of conjugates synthesized using 
SPAAC chemistry was the formation of regioisomers with no apparent preference for a single 
isomer, potentially attributed to flexibility of the linker systems installed on each component.  
While semi-preparative HPLC is unable to resolve the regioisomers, they can be observed as a 
split peak by analytical HPLC when utilizing high peak capacity methods, but show consistent 
mass across the entire analyte peak by LC/MS. We do not anticipate any binding preference for 
either form due to linker flexibility. Importantly, for conjugates employing sulfonate functional 
groups in the linker region, the formation of isomers is possible and would yield an identical mass, 
but is not expected here due to known selectivity of the reactions.  Additional NMR 
characterization data with larger batches is expected to confirm the proposed structures. 
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 Figure 27: 
1H/13C HSQC NMR data for PLP139-151-Alk (top) and PLP139-151-Dex (bottom). 
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3.3.4. Stability and release kinetics 
  Throughout development, the starting peptides were stable in solution for time periods 
relevant to synthesis and analysis of the conjugates (at least a day). Of the therapeutic conjugates 
presented, only PLP139-151-Dex contains an acid-labile ester linkage capable of releasing the 
unadulterated parent drug in acidic microenvironments. Interestingly, the initial hypothesis was 
that Dex release would increase with decreasing pH, however, release of Dex was actually greater 
at pH 7.4 than at pH 5.5 (Figure 28). To better understand this observation, further studies focused 
 
Figure 28: Release of Dex from PLP139-151-Dex as a function of time and buffer, at 37°C.  Starting peptide 
concentration was 1 mg/mL, corrected for potency, and quantified via linear calibration curve. 
on the parent Dex-N3 in conditions that varied the concentration of phosphate buffer, showing 
quicker release as the concentration of phosphate increases (Figure 29). Taken together, it is 
thought that the phosphate anion plays a role in catalyzing the release of Dex from the peptide, 
probably through nucleophilic attack. Therefore, the dosing vehicle for subsequent in vivo studies 
was saline, adjusted to pH 6, to ensure complete solubility of the treatment and prevent premature 
release of Dex. Control experiments with both functionalized and unfunctionalized PLP139-151 did 
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not show any significant degradation in the presence of phosphate buffer under the same 
conditions. 
 
Figure 29: Release of Dex from Dex-N3 as a function of time and buffer, at 25°C.  To maintain Dex solubility for the 
duration of the analysis, the study was completed in 1:1 buffer:MeCN. 
 
3.3.5. Efficacy studies 
Splenocytes harvested from EAE mice at peak of disease provided a model cell system to 
evaluate drug activity, in terms of half-maximal inhibitory concentration (IC50). PLP139-151-Dex 
showed a similar IC50 value when compared to Dex alone (Figure 30), indicating that the drug still 
remained active following conjugation, potentially due to the site selected for conjugation. When 
administered as a treatment regimen in EAE mice, PLP139-151-Dex showed complete suppression 
of disease symptoms, with all mice (N = 5 mice/group) showing no sign of disease throughout the 
duration of the study (Figure 31). Additionally, the mean weight of the PLP139-151-Dex treatment 
group increased over the course of the study, when compared to the PBS control group, which 
showed a decrease in weight correlating to an increase in clinical score (Figure 32). 
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Figure 30: Determination of IC50 for Dex and PLP139-151-Dex in EAE splenocytes. 
 
 
Figure 31: In vivo study in EAE mice, comparing clinical scores of a PLP139-151-Dex treatment group to a PBS control 





Figure 32: In vivo study in EAE mice, comparing normalized weights of a PLP139-151-Dex treatment group to a PBS 
control group.  N=5 mice/group. 
 
3.3.6. AgDCs uniquely combine two therapeutic approaches 
AgDCs present a novel combination of two current treatment strategies, exploiting the 
specificity of the disease-causing autoantigen and potency of an immunomodulatory drug. As 
opposed to current treatments aimed at symptom suppression and reduction of disease progression, 
AgDCs have the potential to reverse autoimmune disease by targeting offending immune cells and 
deleting these cells or inducing tolerance to a specified autoantigen. In vivo studies have shown 
complete suppression of symptoms in the EAE model using PLP as a directing peptide, however, 
a different effect may be observed when the drug is conjugated to full length protein. The BCR is 
thought to be the target of AgDCs, since the BCR is a high affinity receptor. Studies employing 
BCR antibodies to block antigen binding, used in conjugation with fluorescently labeled peptide 
autoantigen may help to elucidate this mechanism. Other less likely mechanisms, such as direct 
binding to MHC II, could be probed in a similar manner. If our hypothesis is correct, conjugating 
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drug directly to full length protein autoantigens would target a wide repertoire of BCRs on B cells 
contributing to autoimmunity. 
 
3.4. Conclusion 
Antigen-drug conjugates (AgDCs) represent a novel class of therapeutics with broad 
applicability to a variety of antigen-specific autoimmune disorders. By harnessing the benefits of 
two traditional therapeutic approaches, hyposensitization and immunomodulatory therapy, AgDCs 
employ a synergistic approach by conjugating the antigen to the immunomodulatory agent. PLP139-
151-Dex showed promising in vivo results that warrant further screening and mechanistic evaluation 
of the AgDC strategy. Experiments to improve understanding of cellular localization and uptake 
will utilize compounds such as PLP139-151-Rhod, which provides a fluorescent probe on the 
antigenic peptide. 
Ongoing efforts to expand the AgDC platform in our laboratory are multi-faceted, from 
expanding the antigen and payload library within the MS indication, to adaption across the 
landscape of antigen-specific autoimmune disorders. The modular nature of this AgDC approach, 
coupled with the consistency and specificity of the chemistries employed, make AgDCs a 
promising therapeutic class for the treatment of autoimmune disorders. Additional AgDCs 
presented in this chapter, including PLP139-151-MMAE, PLP139-151-DM1, and PLP139-151-Dox will 
undergo further evaluation in in vivo or in vitro systems as a continued effort to identify improved 
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CHAPTER 4: MULTIVALENT SOLUBLE ANTIGEN ARRAYS EXHIBIT HIGH AVIDITY BINDING 
AND MODULATION OF B CELL RECEPTOR-MEDIATED SIGNALING TO DRIVE EFFICACY 
AGAINST EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
4.1. Introduction 
Autoimmune diseases such as multiple sclerosis (MS) are typified by a breakdown of 
healthy immune regulation and subsequent misrecognition of self for non-self.105-106 The 
autoimmune breakdown in MS is largely propagated by autoreactive T and/or B cell clonal 
expansion and attack against myelin sheath autoantigens, leading to demyelination and 
neurodegeneration.107-110 Activation of naïve T cells against autoantigen requires two signals from 
an antigen presenting cell (APC): (1) primary antigenic signal delivered through the major 
histocompatibility complex (MHC) on the APC to the T cell receptor (TCR) on the T cell, and (2) 
secondary costimulatory signal (i.e., CD80/CD86) delivered to the cognate receptor (i.e., CD28) 
on the T cell.111-119 B cells, as professional APCs that possess antigen specificity and 
immunological memory, play a particularly pivotal role in immune regulation.120-122 Indeed, loss 
of B cell tolerance has been implicated in numerous autoimmune diseases.123-125 Autoimmune 
therapies targeting B cells have been successful in treating MS (i.e., rituximab), but general B cell 
depletion or inactivation may induce global immunosuppression, trigger adverse side effects, and 
suffer from limited efficacy.126-128 Development of an antigen-specific immunotherapy (ASIT) that 
targets and silences autoreactive B cells in a selective manner would address an important need 
for safer and more effective treatment.129-131  
Modulation of B cells in a direct, antigen-specific manner requires targeting of the B cell 
receptor (BCR).122 Antigen binding to the BCR can trigger receptor clustering and antigen-specific 
B cell activation.132-136 However, continuous antigen binding and occupation of the BCR in the 
absence of secondary costimulatory signals results in B cell anergy, or a state of antigen 
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unresponsiveness, that is marked by reduced calcium signaling.131, 137-139 Induction of B cell anergy 
can have a two-fold therapeutic effect by inducing (1) an effector B cell population that is not 
responsive to autoantigen and (2) B cells with reduced APC capacity due to downregulation of 
costimulatory signals CD80 and CD86.119, 129-130, 140 Thus, a promising avenue for modulating the 
immune response in an antigen-specific manner is to induce these B cell phenotypes through BCR 
engagement.  
Multivalent linear polymers are especially adept at engaging cell surface receptors such as 
the BCR, where high avidity multivalent antigen is aided by the molecule’s conformational 
flexibility to permit greater interaction with the cell surface to bind and cluster receptors.132, 134, 141-
147 For example, the spacing and orientation of ligands on a linear polymer may adapt to the contour 
and dynamic receptor spacing of the cell surface, whereas spherical or globular particles (i.e., 
dendrimers, nanoparticles, liposomes) are inherently more rigid with relatively fixed spacing and 
orientation of ligands. As such, multivalent linear polymers may be particularly suited for B cell 
and BCR targeted therapies. We previously reported on multivalent soluble antigen arrays 
(SAgAPLP:LABL) consisting of a linear hyaluronic acid (HA) polymer co-grafted with myelin 
autoantigen peptide (proteolipid protein peptide, PLP139-151) and intercellular adhesion molecule-
1 (ICAM-1) inhibitor peptide (LABL) derived from leukocyte function associated antigen-1 (LFA-
1).148-154 In this molecule, PLP acts as the primary antigenic signal to drive antigen-specific B cell 
binding, while LABL enhances cellular engagement by targeting ICAM-1, exploiting the ICAM-
1/LFA-1 interaction that promotes and sustains intercellular adhesion.148, 155-158 Our previous 
studies established that in vivo treatment with SAgAPLP:LABL significantly alleviated experimental 
autoimmune encephalomyelitis (EAE), a murine model of relapsing-remitting multiple 
sclerosis.150-154 Importantly, multivalent presentation of both PLP and LABL on a polymer carrier 
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was necessary for therapeutic efficacy,149, 151, 153 and presentation on soluble linear HA was more 
effective than presentation on insoluble PLGA nanoparticles.152 
The SAgAPLP:LABL molecule studied up to this point employed a degradable linker to 
codeliver PLP and LABL. ‘Hydrolyzable SAgAPLP:LABL’ exhibited antigen-specific binding with 
B cells by targeting the BCR, remained on the cell surface for an extended period of time, and 
dampened BCR-mediated signaling in vitro.148 Our results pointed to sustained BCR engagement 
as the molecule’s therapeutic mechanism, so we hypothesized that using non-hydrolyzable 
conjugation chemistry to develop a non-degradable SAgA would enhance and maintain the 
molecule’s action at the cell surface to improve efficacy. Here, we have developed a new version 
of the SAgA molecule, termed ‘click SAgA’ (cSAgAPLP:LABL), using a hydrolytically stable 
covalent conjugation chemistry rather than hydrolyzable grafting of multivalent PLP139-151 and 
LABL peptides to HA using a hydrolyzable oxime bond. We explored whether this non-
hydrolyzable conjugation chemistry improved B cell engagement and modulation of BCR-
mediated signaling, and if in vivo efficacy was correspondingly improved. 
B cell binding, signaling, and therapeutic efficacy in EAE were compared between 
SAgAPLP:LABL (oxime conjugation chemistry) and cSAgAPLP:LABL (‘click’ conjugation chemistry) 
through a combination of in vitro and in vivo studies. Binding avidity was evaluated in 
immortalized human Raji B cells as a model APC system using flow cytometry binding assays 
developed previously.148 Modulation of BCR-mediated signaling was assessed using flow 
cytometry calcium flux assays. Engagement and organization of BCR on the cell surface was 
observed through real-time fluorescence microscopy. Lastly, in vivo efficacy was compared across 




4.2. Materials and Methods 
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore Biomedical 
(Chaska, MN). 11-azido-3,6,9-trioxaundecan-1-amine (NH2-PEG3-N3), N-hydroxysuccinimide, 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 2-(N-
morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-hydroxypropyltriazolylmethyl)amine, 
and sodium ascorbate (NaAsc) were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification. Copper(II) sulfate pentahydrate (CuSO4 • 5H2O) was 
purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized peptides bearing an N-
terminal 4-pentynoic acid (homopropargyl, hp) modification, hpPLP139-151 (hp-
HSLGKWLGHPDKF-OH) and hpLABL (hp-ITDGEATDSG-OH), were originally synthesized 
in our laboratory via solid phase peptide synthesis. Larger quantities of both hpPLP139-151 and 
hpLABL peptides were obtained from Biomatik USA, LLC (Wilmington, DE). Unmodified PLP 
(NH2-HSLGKWLGHPDKF-OH) peptide was purchased from PolyPeptide Laboratories (San 
Diego, CA). Incomplete Freund’s adjuvant (IFA) and killed Mycobacterium tuberculosis strain 
H37RA were purchased from Difco (Sparks, MD). Pertussis toxin was purchased from List 
Biological Laboratories (Campbell, CA). Fluo-4 AM calcium indicator was purchased from 
Thermo Fisher Scientific (Waltham, MA). Immortalized human Raji B cells were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). AffiniPure F(ab’)2 fragment goat anti-
human IgM and AlexaFluor® 647 AffiniPure F(ab’)2 fragment goat anti-human IgM were 
purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). All other chemicals 
and reagents were analytical grade and used as received. 
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4.2.1. Synthesis of alkyne-modified Pennsylvania Green (Penn Green-Alk) 
 
Figure 33: Scheme for the synthesis of Pennsylvania Green alkyne. 
Synthesis of 4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methyl-N-(prop-2-yn-
1-yl)benzamide (Penn Green-Alk) was adapted from Meng et al.97 To a mixture of 2,5-
dioxopyrrolidin-1-yl 4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylbenzoate (55.3 
µmol) in DMF (0.5 mL), propargylamine (61.2 µmol) in 0.5 mL H3BO3 buffer (pH = 8.5, 50 mM) 
was added and stirred at room temperature for 6 hours. The reaction mixture was frozen and 
lyophilized to give the crude product as an orange liquid. The crude product was dissolved in 
DMSO and purified by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear 
gradient from 5-95% MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 30 min, detection at 280 
nm) to give the final product (22.5 mg, 84.7%) as an orange-yellow solid; 1H NMR (400 MHz, 
DMSO-d6) δ 7.99 (s, 1H), 7.93-7.87 (m, 1H), 7.40 (d, J = 7.9 Hz, 1H), 6.85 (br s, 2H), 6.63 (d, J 
= 11.2 Hz, 2H), 4.11 (dd, J = 5.6, 2.5 Hz, 2H), 3.17 (t, J = 2.5 Hz, 1H), 2.08 (s, 3H); HRMS (TOF 




4.2.2. Synthesis of azide-functionalized hyaluronic acid (HA-N3) 
 
Figure 34: Scheme for the synthesis of HA-N3. 
Synthesis of HA-N3 was adapted from Hu et al and Di Meo et al.
159-160 Sodium hyaluronate 
(93.9 μmol, 16 kDa average MW) was added to a 250 mL round bottom flask with stir bar, 
followed by 100 mL of 50 mM MES buffer (pH = 4.0). The mixture was stirred until in solution 
(~15 min) before EDC (23.1 mmol) was added neat, then N-hydroxysuccinimide (18.8 mmol) 
added neat. The mixture was stirred for 5 min before H2N-PEG3-N3 (4.51 mmol) in 20 mL MES 
buffer was added. The solution was then stirred for 24 hours at room temperature before being 
dialyzed in 6-8 kDa cutoff dialysis tubing against 4.5 L of 1.0 M NaCl solution for 24 hours, then 
4.5 L of deionized water (4 x 12 hours). The volume in the bag was then transferred to vials, frozen, 




4.2.3. Synthesis of Soluble Antigen Arrays 
 
Figure 35: General scheme for the synthesis of cSAgAs. 
HA-N3 (2 μmol) was added as a 50 μM solution in deionized H2O to a 250 mL round 
bottom flask with stir bar. Each component peptide (40 μmol) was then added as a ~3 mM solution 
in deionized H2O, followed by a premixed solution of THPTA (70 μmol) and CuSO4 • 5H2O (14 
μmol) in deionized H2O. In the case with fluorescently-labeled variants, a 2.4 mM Penn Green-
Alk solution in DMF (2.0 equivalents relative to HA-N3) was also added. The solution was allowed 
to stir for 1-2 min before a 100 μL aliquot was removed for HPLC analysis. NaAsc (300 μmol) 
was then added to the reaction mixture as a 100 mM solution in deionized H2O. The reaction was 
allowed to proceed under varying conditions depending on the starting components and desired 
valency (cHAPLP: 18 hours at 37°C; cHALABL and cSAgAPLP:LABL: 18 hours at 50°C; fcHA and 
fcHAPLP: 24 hours at 37°C; fcHALABL and fcSAgAPLP:LABL: 24 hours at 50°C). Additional 100 μL 
aliquots were removed throughout the course of the reaction to determine the extent of conjugation. 
Once the target conjugation values were achieved, the reaction solution was transferred to 6-8 kDa 
dialysis tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 x 8 hours), then 4.5 L of deionized 
H2O (5 x 8 hours). The volume in the bag was then transferred to vials, frozen, and lyophilized.  
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4.2.4. Analytical Characterization of Soluble Antigen Arrays 
FTIR spectra were collected on a Bruker Tensor 27 FTIR spectrometer equipped with an 
Attenuated Total Reflectance (ATR) cell. Purified samples were analyzed at ambient temperature 
in the solid state by collecting a total of 32 scans per sample. NMR spectra were collected on a 
Bruker Avance AVIII 500 MHz spectrometer equipped with a dual carbon/proton cryoprobe 
(unless otherwise noted), and all samples were dissolved in 650 μL of D2O for analysis.  
MestReNova 11.0 was used for NMR data analysis. The amide methyl resonance (δ ~ 1.90-2.05 
ppm) of all 1H NMR spectra was normalized to an integration of 3.0, and the sum of all other 
signals in the range of δ ~ 1.0-4.0 ppm was used to ratiometrically determine the number of azide 
functionalization sites during HA-N3 synthesis. 
RP-HPLC and SEC analysis were conducted using a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For the 










)             Equation 1 
where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in the 
reaction, nHA = moles of HA-N3 used in the reaction, Vpre = total reaction volume before NaAsc is 
added, Vsam = volume of “pre-NaAsc” sample removed from reaction mixture, PAt = measured 
peak area of peptide at time t, PAstart = measured peak area of free peptide before NaAsc is added 
to the reaction. General chromatographic conditions employed a Waters XBridge C4, 3.5 μm, 300 
Å stationary phase under ion pairing (0.05% TFA in H2O and MeCN) mobile phase conditions, 




4.2.5. Cell Culture  
Raji B cells (human B lymphocytes, ATCC) were cultured in RPMI-1640 supplemented 
with L-glutamine, 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin (P/S) at 37°C 
and 5% CO2. Cell assays were consistently performed after cells reached confluency (~2 weeks) 
and following no more than 8-10 passages, per ATCC guidelines.  
 
4.2.6. Flow Cytometry Binding Assay 
Association binding studies were performed by flow cytometry (MoFlo XDP Cell Sorter, 
Beckman Coulter Inc., Brea, CA), as previously reported.148 Cell nuclei were stained with Hoechst 
and propidium iodide (PI) was used as a dead cell indicator; data acquisition was triggered off the 
Hoechst signal. Cell samples were warmed to 37°C for 2 min prior to the flow cytometry run. 
Fluorescence was excited using 488, 405, and 640 nm lasers and was collected using 529/28, 
457/40, and 670/30 nm bandpass emission filters.  
To observe maximum steady state binding, cells were mixed with the treatment to achieve 
a final concentration of 1x106 cells/mL immediately before injecting on the flow cytometer. 
Sample concentration was determined from preliminary saturation studies.148 Samples were added 
at an equimolar PLP dose (353 µM PLP for fHAPLP and fSAgAPLP:LABL, or 353 µM LABL for 
fHALABL) and fHA was dosed at 39 µM (the HA molar equivalent to a 353 µM PLP dose of 
fSAgAPLP:LABL) to mimic the dosing scheme from in vivo studies. The sample was allowed to run 
for 5 min to ensure that maximum steady state was established, which occurs after approximately 
3-4 min.  
Flow cytometry binding data was first gated to remove doublets, dead cells, and debris 
using Kaluza Flow Analysis software (Beckman Coulter, Inc., Brea, CA). Additional data 
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processing was performed using KNIME software (Konstanz Information Miner, KNIME, Zurich, 
Switzerland). Nonlinear regression and additional statistical analysis was performed using 
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).  
 
4.2.7. Calcium Flux Signaling Assay 
 Raji B cells were loaded with 5 μM Fluo-4 AM for 30 min at room temperature in PBS, 
then kept on ice in HBSS (Hanks Balanced Salt Solution) containing 1.3 mM Ca2+ and 0.9 mM 
Mg2+ before analysis. Cells were run through a BD FACSFusion cytometer and fluorescence was 
monitored in the 530/30 nm channel. After baseline quantification for ~30 sec, crosslinking goat 
anti-human IgM (Jackson ImmunoResearch) was added at a final concentration of 20 μg/mL to 
stimulate the cells. This concentration was determined from a preliminary study where a range of 
anti-human IgM concentrations (5-40 μg/mL) was evaluated and 20 μg/mL achieved greatest 
stimulation of Raji B cells. Changes in Fluo-4 fluorescence were measured for 1 min to establish 
an anti-IgM stimulated baseline, followed by addition of (c)SAgA treatment (dosed at 353 μM 
PLP, same concentration used in binding studies) to determine the effect on IgM-stimulated 
signaling. Data was acquired for an additional 3 min until steady state was established. To measure 
inhibition of anti-IgM stimulation, (c)SAgAPLP:LABL was added to cells prior to anti-IgM 
stimulation. KNIME was used to process and plot the kinetic data, while Kaluza and GraphPad 
Prism were used for the remaining analysis.  
 
4.2.8. Fluorescence Microscopy 
Live cell imaging of fcSAgA binding and surface IgM clustering was observed under 
fluorescence microscopy (Olympus IX81 Inverted Epifluorescence Microscope) using the same 
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concentrations from flow cytometry association binding experiments. CellASIC ONIX M04S 
Microfluidics Switching Plates and Microfluidics Platform (EMD Millipore, Billerica, MA) were 
utilized for controlled perfusion of fluorescent samples and media with cells during real-time 
imaging. Raji B cells were stained with Hoechst and mixed with AlexaFluor® 647 goat anti-human 
IgM (Jackson ImmunoResearch) at 20 μg/mL to stimulate the cells and label surface IgM, then 
loaded into the imaging chamber. fcSAgA was perfused into the chamber for 10 minutes (3 psi for 
5 minutes, 0.25 psi for 5 minutes) to allow binding with cells, followed by gentle media perfusion 
(0.25 psi for 5 minutes) to rinse unbound fcSAgA, followed by immediate image capture. Images 
were processed using Slidebook 5.5 (Intelligent Imaging Innovations, Inc., Denver, CO) and 
quantitative BCR clustering analysis was performed using ImageJ. Otsu thresholding was applied 
to the IgM channel to identify IgM capping, where cells with a single localized area of IgM 
fluorescence above a brightness threshold of 65 were considered positive for capping. This method 
was applied to 100-250 IgM-positive stained cells per sample to determine % IgM capping. IgM 
pixel intensity was plotted for individual cells (N = 10 per sample) as a function of diameter to 
generate profile plots relative to normalized diameter (d/D) and to determine the maximum IgM 
pixel intensity per cell. 
 
4.2.9. Preclinical EAE Study in Mice 
In vivo studies were carried out with 4-6 week old SJL/J (H-2) female mice purchased from 
Envigo Laboratories (Indianapolis, IN). Mice were housed under specified, pathogen-free 
conditions at the University of Kansas and all experiments were approved by the University’s 
Institutional Animal Care and Use Committee. Complete Freund’s adjuvant (CFA) was made by 
combining IFA and killed M. tuberculosis strain H37RA at a final concentration of 4 mg/mL. 
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Animals were induced with experimental autoimmune encephalomyelitis (EAE), the PLP-specific 
mouse model of relapsing-remitting MS, on day 0 of the study. Immunization was accomplished 
using a 0.2 mL emulsion containing 200 μg PLP139-151 peptide, plus equal volumes of PBS and 
CFA. The emulsion was administered subcutaneously (s.c.) as a total of four 50 μL injections, 
located above each shoulder and each hind flank. Pertussis toxin (100 ng in 100 μL) was injected 
intraperitoneally on day 0 and day 2 post-immunization. 
Treatments were administered on days 4, 7, and 10 as 100 μL subcutaneous injections at 
the nape of the neck (N = 3-6 mice per treatment group), with the exception of one group in the 
dosing study that received treatments on days 4 and 7 only. Samples were administered at a dose 
equivalent to 50, 133, or 200 nmol PLP per 100 μL (0.5, 1.33, or 2 mM PLP, respectively). This 
three-day dosing schedule and dose of 200 nmol PLP were found to be efficacious in a previous 
SAgAPLP:LABL study.
153 Disease progression was evaluated by a single observer using the following 
clinical score system: 0, no clinical disease symptoms; 1, weakness or limpness of the tail; 2, 
weakness or partial paralysis of one or two hind limbs (paraparesis); 3, full paralysis of both hind 
limbs (paraplegia); 4, paraplegia plus weakness or paralysis of forelimbs; 5, moribund (at which 
point mice were euthanized). In addition to animal scoring, body weight measurements were 
performed daily for the 26-day duration of the EAE study. 
 
4.2.10. Statistical Analysis 
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test.  
ANOVA was followed by Tukey’s or Sidak’s post-hoc test, where appropriate. The threshold for 
statistical significance was set to p<0.05. 
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4.3. Results and Discussion 
4.3.1. Structural design of click soluble antigen arrays 
Multivalent soluble antigen arrays (SAgAPLP:LABL) consist of a 16 kDa HA linear polymer 
conjugated with approximately 10 PLP and 10 LABL peptides. The molecule was rationally 
designed based on studies by Dintzis et al. that suggested multivalent linear polymers with a 
valency of 10-20 antigens and MW<100 kDa could induce a tolerogenic immune response,146, 161-
162 combined with studies by Siahaan et al. that showed linking PLP and LABL peptides in a 
bifunctional molecule was therapeutic in EAE.157-158, 163-167 Previous SAgAPLP:LABL molecules 
studied in our research group employed a hydrolyzable linker chemistry to conjugate both PLP139-
151 and LABL peptides to HA, and have been shown to significantly suppress disease severity in 
EAE.148-154 This approach was built upon our earlier two-signal hypothesis that SAgAPLP:LABL 
inhibited autoimmune activation via the immunological synapse by promoting antigen processing 
without the necessary secondary signal, a mechanism that would necessitate antigen uptake, 
processing, and presentation. However, our recent in vitro studies instead pointed to a therapeutic 
mechanism in which SAgAPLP:LABL acted through sustained BCR engagement, targeting BCR 
signaling while exhibiting prolonged residence on the cell surface.148 Whereas our early hypothesis 
motivated a degradable SAgA molecule to permit antigen uptake and processing, these results 
motivated the development of a non-degradable SAgA molecule to enhance and maintain the 
molecule’s surface activity. Thus, we synthesized ‘click’ cSAgA variants that exploit a non-
cleavable linker chemistry to evaluate whether possible release of PLP139-151 and LABL influenced 
the efficacy of the molecule. cSAgA multivalent arrays utilize the Copper-catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) reaction as a stable attachment chemistry, which carries significant 
literature precedence with respect to application168-169 and optimization170-171. The versatility of the 
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CuAAC reaction was a major consideration in the implementation of an alternative conjugation 
chemistry, since the wide range of available reaction conditions can enable improved control over 
valency. 
 
4.3.2. Analytical characterization of click soluble antigen arrays 
Characterization was completed using a variety of qualitative and quantitative analytical 
techniques. Initial azide-functionalization was confirmed by FTIR spectroscopy, showing the 
presence of a characteristic azide stretching band after synthesis of HA-N3, which disappeared 
following utilization of the azide moiety during conjugation (Figure 36). Quantitation by 1H NMR 
proved challenging due to signal broadening of the increasingly heterogeneous polymeric systems, 
and the high molecular weight of the multivalent arrays led to decreasing sensitivity with 
increasing conjugation, eventually limited by sample solubility. For an analysis of azide 
functionalization, integration ranges were used to account for signal overlap between the polymer 
backbone resonances and those on the linker. To assess the validity of this approach, two additional 
batches of HA-N3 were prepared using a reduced number of molar equivalents of linker relative to 
the starting HA, resulting in a reduced number of azide functionalized sites (Table 1).  





Average N3 Sites per 
Polymer 
Batch #1 48 50 21 
Batch #2 25 45 19 
Batch #3 12 31 13 




It should be noted, however, that manual integration was required to perform this analysis, and 
coupled with the broad resonances observed from the polymeric system, this technique is 
considered to be a semi-quantitative approach to justify subsequent peptide conjugation. 
Additional NMR studies in the solid-state or observation of alternative nuclei may aid in the 
quantitative nature of the analytical methodology. 1H/13C Heteronuclear Single Quantum 
Coherence (HSQC) NMR spectroscopy was used qualitatively to confirm the existence of 
resonances present in both peptide samples, which carried over to the final dialyzed products 
(Figure 37). Importantly, these experiments also showed the disappearance of the terminal alkyne 
resonance from the linker on each peptide along with the concomitant appearance of a broadened 
aromatic resonance not present in any individual component, corresponding to the new triazole 
ring. 
 
 Figure 36: FTIR spectra collected after functionalization and conjugation of HA. 
Quantitative analysis of peptide conjugation efficiency was conducted via RP-HPLC by 
measuring the decrease in peak area of the free alkyne-containing peptide(s) throughout the course 

















Figure 37: Qualitative confirmation of conjugation by 2D HSQC NMR where a 1H spectrum is shown on the x-axis 
and a 1H-decoupled 13C spectrum is shown on the y-axis. 
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to proceed, which is generated in situ through addition of the reducing agent NaAsc to an inactive 
Cu2+ in solution. Prior to this final NaAsc addition step, an aliquot of the reaction mixture was 
removed for HPLC analysis to establish a baseline response correlating to the molar excess of 
peptide used in the reaction. Subsequent to the addition of NaAsc, any decrease in peak area of 
free alkyne-containing peptide was attributed to conjugation (Figure 38). Standard curves for both 
peptides were linear to 110% of the nominal concentrations used in the reaction mixture (0.81 mM 
for hpPLP139-151 and 0.71 mM for hpLABL), exhibiting R
2 values >0.99 upon linear regression 
analysis. Additional control experiments showed both hpPLP and hpLABL displayed <5% 
degradation (0.8% and 4.5%, respectively) at 37°C in H2O over 20 hours in the absence of all other 
reaction components, indicating a minimal impact of peptide degradation on the accuracy of the 
analytical methodology.  
 
Figure 38: Representative HPLC chromatograms used to quantify the number of conjugated peptides as a function of 
reaction temperature. 
Further, the final dialyzed products showed no evidence of peptide release after 18 hours at room 
temperature in either pH ~ 2.4, 5.0, or 7.0 buffers, confirming the basis behind the non- 
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hydrolyzable linker design of the cSAgA molecular platform (Figure 39). An abbreviated reaction 
optimization study showed that conjugation ratios could be significantly influenced by buffer, 
temperature, reactant concentrations, and molar excess of free peptide. From these observations, 
reaction conditions were identified that achieved a desired peptide valency. Quantitative peptide 
conjugation of representative test articles is provided in Table 2, showing that target conjugation 
efficiencies of approximately 25% per peptide (relative to theoretically available disaccharide 
monomers) were achieved in cHAPLP (10 PLP139-151), cHALABL (12 LABL), and cSAgAPLP:LABL 
(11 PLP139-151, 9 LABL). Size exclusion chromatography (SEC) was primarily used to verify the 
success of dialysis, showing no evidence of free peptide or other reaction components in any 
purified cSAgA samples (Figure 40). HA samples of varying molecular weight were used as 
standards to compare against purified reaction products. HA-N3 exhibited a slight decrease in 
retention time compared to 16 kDa HA, indicating an increase in molecular weight following azide  
 
Figure 39: Reverse-phase analytical high-performance liquid chromatography (RP-HPLC) from a room temperature 
solution stability study of cHAPLP at pH 2.4 (measured pH of aqueous component of mobile phase, 0.05% TFA in 
H2O), showing negligible degradation and release of PLP. This study was also conducted at pH 5.0 (100 mM acetate 




functionalization. Retention time increased following peptide conjugation; however, this was 
likely a reflection of the molecule’s altered physicochemical properties and increased secondary 
interactions with the stationary phase rather than a reflection of molecular size. Given that 
hpPLP139-151 eluted after the retention time observed for salts, the increased retention of peptide-
conjugated samples was likely due to secondary interactions between peptide in solution and the 
stationary phase overcoming the primary interactions that drive SEC separation. This secondary 
interaction was evident throughout method development regardless of mobile phase pH, salt 
concentration, and stationary phase composition.  
 
Figure 40: Size exclusion chromatography (SEC) for fluorescently-labeled multivalent arrays. The top overlay shows 
the full length chromatogram, and the bottom overlay shows normalized expansion of the HA-containing species. 
Chromatographic conditions – column: Waters XBridge SEC, 125 Å, 3.5 μm, 7.8x300 mm; Mobile phase: 50mM 
phosphate (pH 7.0) with 0.2M NaCl; Flow rate: 0.8 mL/min; Detection: UV at 214 nm. Samples were prepared in 




4.3.3. Flow Cytometry Binding Assay 
A flow cytometry binding assay was used to compare the relative binding avidities of 
hydrolyzable fSAgA and click-conjugated fcSAgA with Raji B cells. Binding kinetics were 
observed during association between the fluorescently labeled polymer arrays and Raji B cells 








PLP:HA LABL:HA PLP LABL 
HAPLP 
 
30.4 9 0 21 0 
HALABL 
 
26.0 0 10 0 24 
SAgAPLP:LABL 
 
46.3 10 13 24 31 
cHAPLP 
 
41.2 10 0 24 0 
cHALABL 
 
37.2 0 12 0 28 
cSAgAPLP:LABL 
 
52.1 11 9 26 21 
a Results are an average of triplicate injections from a single batch preparation. In the molecule schematics, dotted 
lines represent hydrolyzable oxime linker chemistry while solid lines represent non-hydrolyzable ‘click’ linker 
chemistry. 
b Calculated from RP-HPLC data. MW, molecular weight. 





until maximum steady state (max. SS) was reached (illustrated in Figure 41A). It was previously 
observed that fSAgAPLP:LABL, co-grafted with both PLP139-151 and LABL, exhibited greater binding 
with Raji B cells than the polymer alone (fHA) or the homopolymers grafted with only one signal 
(fHAPLP or fHALABL).
148 A similar trend was observed with click-conjugated arrays: 
fcSAgAPLP:LABL exhibited the highest amount of binding, followed by fcHAPLP, while fcHA 
exhibited the lowest amount of binding (Figure 42A). Comparison of the maximum SS indicated 
that fcSAgAPLP:LABL binding was significantly greater than that of fcHAPLP, fcHALABL, and fcHA, 
while fcHAPLP binding was significantly greater than that of fcHALABL and fcHA (Figure 42B). 
Thus, multivalent PLP139-151 and LABL appear to have a cooperative effect on avidity. We 
previously reported that SAgAPLP:LABL exhibited PLP-specific binding and BCR targeting, 
implying that PLP may enhance B cell avidity by providing specific affinity for the BCR.148 
Meanwhile, LABL, derived from LFA-1 and specific for ICAM-1, may enhance B cell avidity by 
promoting cell adhesion through the LFA-1/ICAM-1 interaction.111, 115-117, 155-158, 172 ICAM-1 and 
LFA-1 expression are upregulated on B cells during surface BCR engagement to promote 
intercellular adhesion, since the ICAM-1/LFA-1 interaction is critical for B cell:T cell conjugate 
formation during signaling.173 This may explain why multivalent LABL exerted a cooperative 
effect on binding avidity when presented alongside PLP in fcSAgAPLP:LABL, but a minimal effect 
when presented alone in fcHALABL. 
Comparison of click-conjugated versus hydrolyzable compound binding revealed that both 
fcSAgAPLP:LABL and fcHAPLP exhibited significantly enhanced binding compared to their 
hydrolyzable counterparts, fSAgAPLP:LABL and fHAPLP, respectively (Figure 42C). Differences in 
kinetics and maximum SS binding between fcSAgAPLP:LABL, fSAgAPLP:LABL, and fHA illustrate 




Figure 41: Comparing SAgAPLP:LABL and cSAgAPLP:LABL binding and IgM-stimulated (BCR-mediated) calcium flux 
signaling in Raji B cells through flow cytometry assays: (A) Binding kinetics and (B) maximum steady state (max. SS) 
binding with fSAgAPLP:LABL, fcSAgAPLP:LABL, and fcHA. (C) Calcium flux inhibition: Fluo-4 loaded cells were first 
pretreated with vehicle (HBSS), SAgAPLP:LABL, or cSAgAPLP:LABL, then stimulated with anti-IgM (αIgM, black arrow) 
to evaluate signaling inhibition. (D) Relative IgM signaling stimulation following pretreatment; baseline-adjusted 
values determined from mean steady state values. (E) Calcium flux reduction: Fluo-4 loaded cells were first stimulated 
with αIgM at ~30 s (black arrow), then treated with vehicle (HBSS), SAgAPLP:LABL, or cSAgAPLP:LABL after ~60 s 
(black arrow) to evaluate signaling reduction. (F) Percent reduction from IgM-stimulated baseline following sample 
addition, determined from mean steady state values. Statistical significance was determined by ANOVA followed by 
Tukey’s post hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Calcium flux kinetics 
in (C) and (D) show median Fluo-4 fluorescence values. Robust curve fitting in (A) was performed using sigmoidal 





Figure 42: Binding of fcHA, fcHALABL, fcHAPLP, and fcSAgAPLP:LABL with Raji B cells determined by flow cytometry: 
(A) Binding kinetics showing association through steady state. (B) Relative binding at maximum steady state (max. 
SS). (C) Comparison of max. SS binding with hydrolyzable versus click-conjugated arrays. Statistical significance 
determined by ANOVA followed by Tukey’s (B) or Sidak’s (C) post hoc test with p<0.05 and n=3 (*p<0.05, **p<0.01, 




non-hydrolyzable manner (Figure 41AB). While both methods of multivalent modification 
resulted in significantly increased binding compared to the polymer alone, click-conjugated 
fcSAgAPLP:LABL exhibited significantly greater maximum SS binding (p<0.001) than hydrolyzable 
SAgAPLP:LABL. Thus, multivalent co-presentation of PLP and LABL through non-hydrolyzable 
modification increased the avidity of the polymer array more than hydrolyzable modification.  This 
result is supportive of literature stating that multivalent antigens exhibit superior binding avidity, 
higher ‘effective concentration’, and an enhanced ability to engage cell receptors compared to 
monovalent (or in this case, hydrolyzable) antigen.131, 142-143, 145, 174  
 
4.3.4. Calcium Flux Signaling Flow Cytometry Assay 
Flow cytometry calcium flux assays were used to compare the ability of SAgA and cSAgA 
molecules to modulate BCR-mediated signaling in Raji B cells. Signaling modulation was 
evaluated in Fluo-4 loaded Raji B cells prior to stimulation (Figure 41CD) and after stimulation 
(Figure 41EF) with crosslinking αIgM. The relative signal increase from resting baseline (Figure 
41D) or reduction from stimulated baseline (Figure 41F) was determined using mean Fluo-4 
fluorescence values at steady state.  
We reported previously that SAgAPLP:LABL was capable of both inhibiting and reducing 
IgM-stimulated signaling.148 Here, pre-treatment with SAgAPLP:LABL prior to addition of αIgM 
significantly inhibited IgM-stimulated calcium signaling compared to the vehicle (p<0.05) (Figure 
41CD). However, pre-treatment with cSAgAPLP:LABL significantly inhibited IgM-stimulated 
calcium signaling to a greater extent (p<0.01), largely preventing even the initial spike in calcium 
flux observed with SAgAPLP:LABL after αIgM addition. Similarly, addition of cSAgAPLP:LABL after 
αIgM stimulation caused a greater reduction in calcium signaling than SAgAPLP:LABL (p<0.01) 
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(Figure 41EF). cSAgAPLP:LABL reduced signaling by ~60% while SAgAPLP:LABL reduced signaling 
by ~40% relative to the vehicle control. These results indicated that click-conjugated 
cSAgAPLP:LABL was significantly more effective at dampening BCR-mediated signaling – both 
through inhibition and reduction – compared to its hydrolyzable counterpart. 
 
Figure 43: Reduction in IgM-stimulated (BCR-mediated) calcium flux signaling in Fluo-4 loaded Raji B cells 
determined by flow cytometry: (A) Percent reduction from αIgM-stimulated baseline following addition of cHA, 
cHALABL, cHAPLP, or cSAgAPLP:LABL, determined from mean steady state values. (B) Comparison of reduction in αIgM-
stimulated signaling from hydrolyzable versus click-conjugated arrays. Data was pooled from three independent 
experiments. Statistical significance was determined by ANOVA followed by Tukey’s post hoc test (A) or unpaired t-
test (B) with p<0.05 and n=3 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
Previously, we reported a significant reduction in signaling from addition of SAgAPLP:LABL, 
HAPLP, and HALABL, but negligible change in signaling from addition of vehicle (HBSS) or HA.
148 
The click conjugates exhibited a similar trend: cSAgAPLP:LABL caused the greatest reduction in 
signaling while cHA caused the smallest reduction (p<0.05) (Figure 43A). However, while 
cSAgAPLP:LABL caused a greater reduction than hydrolyzable SAgAPLP:LABL, there was not a 
significant difference between cHAPLP vs. HAPLP and cHALABL vs. HALABL (Figure 43B). It is also 
interesting to note that cHA (HA-N3) caused a greater reduction than unmodified HA, which may 
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be due to the presence of azide groups on the HA backbone leading to a greater degree of 
nonspecific binding. 
 
4.3.5. Fluorescence Microscopy 
Fluorescence microscopy was performed using a microfluidics platform that enabled real 
time observation of binding and BCR clustering on the cell surface. Previously, we observed that 
fSAgAPLP:LABL binding induced mature receptor clustering in Raji B cells while the polymer alone 
did not, and concluded that LABL may contribute to the SAgAPLP:LABL molecule’s ability to cluster 
receptors.148 Here, we observed receptor clustering following binding and also labeled IgM to 
monitor BCR organization on the cell surface. Negative control cells treated with media exhibited 
diffuse BCR staining (Figure 44A), while cells treated with fcHALABL (Figure 44C), fcHAPLP 
(Figure 44D), and fcSAgAPLP:LABL (Figure 44E) exhibited BCR capping. BCR capping occurs 
when BCR clusters coalesce to form a single aggregate (i.e., one area of high intensity IgM 
fluorescence).175 In contrast, cells treated with unmodified fcHA polymer exhibited BCR 
microclustering, which occurs when BCR clusters fail to coalesce into a single aggregate (i.e., 
multiple areas of moderate intensity IgM fluorescence) (Figure 44B). BCR capping on individual 
cells was quantified by plotting IgM pixel intensity relative to normalized cell diameter (Figure 
45A), revealing that fcHALABL, fcHAPLP, and fcSAgAPLP:LABL induced clusters with significantly 
higher IgM intensity than the vehicle or fcHA (Figure 45B). Additionally, fcHALABL, fcHAPLP, 
and fcSAgAPLP:LABL induced IgM capping in a significantly higher fraction of cells than the vehicle 
or fcHA (Figure 45C). fcHALABL and fcSAgAPLP:LABL appeared particularly adept at inducing a 
high degree of IgM capping in a large fraction of cells. These trends echoed our previous 




Figure 44: Fluorescence microscopy showing binding and BCR clustering in Raji B cells following perfusion of (A) 
vehicle, (B) fcHA, (C) fcHALABL, (D) fcHAPLP, and (E) fcSAgAPLP:LABL. Cell nuclei were stained with Hoechst (violet – 
Panel 1) and surface IgM was stained with AlexaFluor® 647-conjugated αIgM (blue – Panel 3). Penn Green-labeled 
polymer arrays are shown binding to the cell surface (green – Panel 2). In contrast to the diffuse IgM fluorescence in 
(A), highly localized punctate IgM fluorescence in (C), (D), and (E) indicates BCR clustering and capping in cells 
treated with fcHALABL, fcHAPLP, and fcSAgAPLP:LABL. Capping occurs when BCR clusters coalesce to form a single 
aggregate (i.e., one area of high intensity IgM fluorescence). Captured using the M04S plate and CellASIC Onyx 
Microfluidics platform on an Olympus IX81 inverted Epifluorescence microscope. Magnification: 60X air. Scale bar 




HA, induced mature receptor clustering.148 PLP may promote clustering due to its antigen-specific 
affinity for BCR. LABL may promote clustering due to its affinity for ICAM-1, which (along with 
LFA-1) plays an integral role in the organization of supramolecular activation clusters (SMACs) 
during BCR signaling by forming a peripheral ring (pSMAC) around the central BCR cluster 
(cSMAC).111, 156, 176-177 
 
Figure 45: Quantification of BCR clustering in Raji B cells following perfusion of vehicle, fcHA, fcHALABL, fcHAPLP, 
or fcSAgAPLP:LABL in the microfluidics plate. (A) Representative cell profile plots of IgM pixel intensity relative to 
normalized cell diameter, d/D. (B) Maximum IgM pixel intensity per cell determined from profile plots of individual 
cells (n=10). (C) Percent of cells positive for IgM capping (fully coalesced IgM clustering) determined using otsu 
thresholding (n=100-250 cells per sample). Statistical significance was determined by ANOVA followed by Tukey’s 
post hoc test with p<0.05 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Mean + SD shown. Images were 
captured using the M04S plate and CellASIC Onyx Microfluidics platform on an Olympus IX81 inverted 
Epifluorescence microscope and analyzed in ImageJ. 
It has been suggested that quantitative differences in the degree of BCR clustering and 
crosslinking may drive qualitative differences in BCR signaling. 178 In general, our observations 
of BCR clustering corroborated our calcium flux results, since cHAPLP, cHALABL, and in particular 
cSAgAPLP:LABL reduced BCR-mediated signaling to a greater extent than cHA. Combined with 
previous evidence supporting BCR as a target for SAgAPLP:LABL binding,
148 these results suggested 
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that cSAgAPLP:LABL engagement and subsequent clustering of the BCR may dampen signaling. Our 
observations are consistent with reports that continuous BCR engagement and clustering are a 
mechanism for inducing B cell anergy that is accompanied by reduced calcium flux signaling.138-
139  
 
4.3.6. Preclinical EAE Studies 
 Therapeutic efficacy of SAgAPLP:LABL and cSAgAPLP:LABL was evaluated in EAE mice 
induced with PLP139-151 to model the relapsing-remitting form of MS. Disease symptoms emerged 
on day 10-12 with peak of disease occurring on day 13-15 before progressing to remission around 
day 20-25. Efficacy was measured by clinical score, weight change, and clinical score area under 
the curve (AUC) relative to the PBS control. AUC representation of clinical data has been reported 
as an informative secondary measure for overall extent of disease because it provides a cumulative 
measure not weighted by the scaling or time course of disease.179 Disease incidence and mortality 
rate are provided as supplemental information (Figure 46). Statistical differences were determined 
by comparing treated groups with the negative PBS control. 
 A three-day dosing schedule with a dose equivalent to 200 nmol PLP139-151 administered 
on days 4, 7, and 10 was found to be efficacious in previous SAgAPLP:LABL studies.
149-154 This dose 
and schedule were mirrored in a preliminary in vivo study with cSAgAPLP:LABL. It is important to 
note that shortly after the third administration on day 10, five out of six mice that received 
cSAgAPLP:LABL died from apparent anaphylaxis. This result may be due to a greater effective 
concentration of PLP antigen being delivered to immune cells with the click-conjugated platform 
over the acid-labile platform. As is the case with allergen tolerization therapy, where an offending 




Figure 46: Comparing SAgAPLP:LABL and cSAgAPLP:LABL therapeutic efficacy in EAE: (A) incidence of disease and (B) 
mortality in mice treated with SAgAPLP:LABL (200 nmol PLP dose) (n=6); (C) incidence of disease and (D) mortality 
in mice treated with cSAgAPLP:LABL (50 nmol PLP dose) versus SAgAPLP:LABL (50 nmol PLP dose) (n=5). 
response, care must be taken to achieve an effective cumulative dose that induces tolerance 
without activating a severe hypersensitive response. 180-182 Our observation reflects the greater 
potency of cSAgAPLP:LABL compared to SAgAPLP:LABL, such that a lower dose was required to 
tip the immune response towards severe hypersensitivity. Therefore, a combination of lower 
doses was investigated in a small-scale dosing study (Figure 47). To determine whether the total 




Figure 47: Clinical EAE dosing study with cSAgAPLP:LABL: cSAgAPLP:LABL was administered on days 4 and 7 at a dose 
equivalent to 200 nmol PLP and on days 4, 7, and 10 at a dose equivalent to 50 or 133 nmol PLP. Therapeutic efficacy 
evaluated by comparing (A) clinical disease score, (B) percent weight change, and (C) clinical score area under the 
curve (AUC). Statistical significance (compared to the negative PBS control) was determined by ANOVA followed by 




with the same dose per injection (200 nmol PLP139-151) but administered only on two days (days 
4, 7). In another group, an equivalent cumulative dose was administered over three days (133 
nmol PLP139-151 on days 4, 7, 10). A final group was included with a low dose of 50 nmol PLP139-
151, administered on all three days. All dosing groups significantly alleviated disease compared 
to the PBS control according to clinical disease score (Figure 47A) and clinical score AUC 
(Figure 47C). The cSAgAPLP:LABL dose of 50 nmol PLP139-151 caused a significant reduction in 
clinical score on the greatest number of days (days 12-18) and exhibited the greatest reduction 
in clinical score AUC compared to PBS (p<0.001). Therefore, a cSAgAPLP:LABL dose of 50 nmol 
PLP139-151 was selected for studies going forward. 
 Next, in vivo efficacy of click-conjugated cSAgAPLP:LABL was compared to hydrolyzable 
SAgAPLP:LABL (Figure 48). At the original therapeutic dose equivalent to 200 nmol PLP139-151, 
SAgAPLP:LABL significantly reduced clinical score on days 11-20 (Figure 48A) and significantly 
reduced total disease score AUC compared to PBS (p<0.0001) (Figure 48E). At only a quarter of 
the dose, cSAgAPLP:LABL (50 nmol PLP139-151) significantly reduced total clinical score AUC to an 
equivalent extent as SAgAPLP:LABL at 200 nmol PLP139-151 (Figure 48E). Furthermore, 
cSAgAPLP:LABL (50 nmol PLP139-151) significantly reduced clinical score on days 10-17 to a greater 
extent than SAgAPLP:LABL at the 200 nmol dose (Figure 48B). In contrast, the 50 nmol dose of 
SAgAPLP:LABL significantly reduced clinical score only on days 11 and 14 (Figure 48B), and 
reduced clinical score AUC to a significantly lesser extent (p<0.001) than cSAgAPLP:LABL (50 nmol 
PLP139-151) (Figure 48E). While SAgAPLP:LABL (200 nmol PLP139-151) significantly alleviated 
weight loss on days 11-22 (Figure 48C), cSAgAPLP:LABL (50 nmol PLP139-151) significantly 
alleviated weight loss over a larger portion of the study, on days 11-25 (Figure 48D). In contrast, 
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SAgAPLP:LABL (50 nmol PLP139-151) did not alleviate weight loss on any day of the study (Figure 
48D).  
Lastly, cSAgAPLP:LABL (50 nmol PLP139-151) reduced incidence of disease to a greater extent 
than SAgAPLP:LABL at either dose (Figure 46). During peak of disease, 100% of the mice treated 
with PBS or SAgAPLP:LABL (50 nmol PLP139-151) and over 75% of the mice treated with 
SAgAPLP:LABL (200 nmol PLP139-151) exhibited disease symptoms. In contrast, less than 25% of the 
mice treated with cSAgAPLP:LABL (50 nmol PLP139-151) exhibited disease symptoms during peak of 
disease. Therefore, when considering multiple measures of efficacy, cSAgAPLP:LABL achieved 
equivalent or greater in vivo efficacy as SAgAPLP:LABL at one quarter of the antigen dose. We 




Click-conjugated multivalent soluble antigen arrays were developed and evaluated in vitro 
and in vivo as therapeutic agents in a murine model of MS. Hydrolyzable SAgAPLP:LABL, which we 
have studied extensively and shown to significantly suppress EAE,148-154 employed a degradable 
linker to co-deliver antigen (PLP) and cell adhesion inhibitor (LABL) peptides. This approach was 
built upon our earlier two-signal hypothesis that SAgAPLP:LABL inhibited autoimmune activation 
via the immunological synapse, a mechanism that would necessitate antigen uptake, processing, 
and presentation and motivated the design of a degradable SAgA molecule. Recent in vitro studies, 




Figure 48: Comparing SAgAPLP:LABL and cSAgAPLP:LABL therapeutic efficacy in EAE: (A) SAgAPLP:LABL (200 nmol PLP 
dose) clinical scores (n=6), (B) cSAgAPLP:LABL versus SAgAPLP:LABL (50 nmol PLP dose) clinical scores (n=5), (C) 
SAgAPLP:LABL (200 nmol PLP dose) weight change, (D) cSAgAPLP:LABL versus SAgAPLP:LABL (50 nmol PLP dose) weight 
change, and (E) clinical score area under the curve (AUC) relative to PBS. Statistical significance was determined 





sustained BCR engagement, targeting BCR signaling while exhibiting prolonged residence on the 
cell surface.148 These results motivated the development of a non-degradable SAgA molecule to 
enhance and maintain the molecule’s surface activity, which we hypothesized would improve 
therapeutic efficacy. cSAgAPLP:LABL was developed as a modified version of the SAgAPLP:LABL 
molecule with multiple PLP139-151 and LABL peptides conjugated to HA using non-hydrolyzable 
linker chemistry (Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC)). 
Building upon previous work, these studies sought to establish therapeutic efficacy of 
cSAgAPLP:LABL in vivo while identifying a potential therapeutic mechanism by evaluating binding 
avidity and signaling modulation in vitro. Click-conjugated cSAgAPLP:LABL exhibited greatly 
enhanced binding in B cells compared to hydrolyzable SAgAPLP:LABL, indicating that non-
hydrolyzable multivalent ligand increased the avidity of the molecule. Furthermore, 
cSAgAPLP:LABL exhibited greater capacity for reducing and inhibiting BCR-mediated signaling as 
compared to SAgAPLP:LABL. Imaging revealed that cSAgAPLP:LABL binding caused BCR clustering, 
another marker indicative of BCR engagement and signaling modulation. Our in vitro observations 
pointed to B cell anergy, induced by continuous BCR engagement and clustering and accompanied 
by reduced calcium flux signaling, as a likely cSAgAPLP:LABL therapeutic cellular mechanism. 
Lastly, cSAgAPLP:LABL exhibited enhanced in vivo efficacy against EAE, achieving equivalent 
therapeutic efficacy as SAgAPLP:LABL at one quarter of the dose. Taken together, these results 
indicated that non-hydrolyzable conjugation increased the avidity of cSAgAPLP:LABL, driving in 
vivo efficacy through modulated BCR-mediated signaling. The click-conjugated cSAgAPLP:LABL 












CHAPTER 5:  
HYALURONAN-DEXAMETHASONE CONJUGATE AS A PH-




CHAPTER 5: HYALURONAN-DEXAMETHASONE CONJUGATE AS A PH-SENSITIVE DRUG 
DELIVERY SYSTEM 
5.1. Introduction 
The antigen-specific immunotherapies described in Chapters 3 and 4 showed great 
promise, however, many inflammatory diseases lack a known antigen-specific autoimmune 
component. The construction of the hyaluronic acid (hyaluronan, HA) and dexamethasone (Dex) 
building blocks discussed in previous chapters provided a unique opportunity to develop an 
extended release delivery system capable of remaining at the site of action and releasing Dex over 
time. HA has seen extensive clinical use in eye surgeries in combination with Dex to manage post-
surgical inflammation. This provides motivation to explore a bioconjugate to locally address post-
surgical ocular inflammation. 
The corneal endothelium is a monolayer of cells that acts as a barrier and active fluid pump 
system, functioning to maintain corneal transparency and a normal thickness of approximately 5 
μm.183-184 It is widely accepted that cataract surgery results in corneal endothelial cell loss 
(ECL),185-187 and the extent is dependent upon a number of pre-, intra-, and post-operative 
factors.188 Complications following cataract surgeries resulting in significant ECL can lead to 
corneal edema or decomposition, which is associated with decreased vision.185 The current 
standard of care is phacoemulsification which can vary by surgical technique, anterior chamber 
depth, and ultrasound time and energy, and has been shown to induce the formation of highly 
reactive free radicals,189 all of which can contribute to the amount of ECL. Minimization of ECL 
during surgery is a priority and has been assisted by the use of ophthalmic viscoelastic devices 
(OVDs) to stabilize the anterior chamber at various steps in the procedure185 to reduce damage by 
free radicals190 in an effort to protect the integrity of the corneal endothelium.191-193 
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Viscoelastic agents used in OVDs have been employed in intraocular surgeries since the 
1970’s, and variant OVDs have emerged with discrete properties to fit the specific medical need, 
typically modifying the concentration or molecular weight (MW) of the viscoelastic substance to 
influence cohesive, dispersive, or other mechanical properties.194 Of the viscoelastic agents 
commonly used in OVDs, HA is the most popular.195 HA is a naturally-occurring linear 
disaccharide polymer present throughout the body, from the extracellular matrix of connective 
tissue to the aqueous humor and vitreous of the eye, totaling 15 grams for a typical individual.196 
It also plays an important role regulating tissue repair and disease state, such as activation of an 
innate inflammatory response to injury.197 HA is composed of D-glucuronic acid and N-acetyl-D-
glucosamine linked by a β-1,3 glucuronidic bond, and can vary widely in molecular weight, often 
exceeding one million daltons.198 Commercially available OVDs such as Healon® 5 (2.3% HA, 
MW = 4 million daltons) and DisCoVisc® (1.6% HA, MW – 1.7 million daltons) employ high 
MW HA, but newer products such as Twinvisc® and Duovisc® contain two different MW HA.192 
One primary challenge following cataract surgery is the need to manage post-operative 
intraocular inflammation using anti-inflammatory agents. A number of clinical studies have 
demonstrated the use of these agents, often included with an anti-infective drug to control the risk 
of infection.199-204 Dex has been approved for ophthalmic use in multiple products where a risk of 
infection is present, including intravitreal implants,205-206 topical ointments,207 and suspensions. 
However, a setback to the effective management of post-operative inflammation is the requirement 
for frequent dosing, often requiring administration up to 4 times daily. This results in the potential 
for decreased patient compliance and reduced efficacy, especially in elderly patient populations. 
Here, we developed a novel HA-Dex conjugate, where Dex is linked to HA via a labile covalent 
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bond to enable sustained, local release of Dex as a promising alternative for management of 
intraocular inflammation.   
 
5.2. Materials and Methods 
Hyaluronic acid (HA) sodium salt (MW 16 kDa) was purchased from Lifecore Biomedical 
(Chaska, MN). N-hydroxysuccinimide, dexamethasone, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), 2-(N-morpholino)ethanesulfonic acid sodium salt 
(MES), tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), and sodium ascorbate (NaAsc) 
were purchased from Sigma-Aldrich (St. Louis, MO). Copper(II) sulfate pentahydrate (CuSO4 • 
5H2O) was purchased from Acros Organics (Geel, Belgium). 2,5-dioxopyrrolidin-1-yl 2-
azidoacetate was purchased from Clickchemistrytools, LLC (Scottsdale, AZ). All other chemicals 
and reagents were analytical grade and were used as received without further purification. 
 
5.2.1. Synthesis of azide-functionalized dexamethasone (Dex-N3) 
 
Figure 49: Reaction scheme for the synthesis of Dex-N3. 
Dexamethasone was added to a flame dried 250 mL round bottom flask with a stir bar and 
septa. Anhydrous MeCN was added under nitrogen, then DIPEA via a glass syringe. The flask was 
stirred for 10 min before azidoacetic acid NHS ester was added as a powder. The reaction mixture 
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was stirred overnight at room temperature before being analyzed by HPLC. Additional equimolar 
aliquots of azidoacetic acid NHS ester were added, followed by stirring for 2 hours at room 
temperature and analysis by HPLC, until no additional benefit was observed. The crude reaction 
mixture was evaporated under reduced pressure, then dissolved in 4:6 MeCN:H2O and purified by 
prep HPLC. The resulting column fractions were evaporated under reduced pressure to yield the 
final product as a white powder. 1H NMR (500 MHz, DMSO-d6) δ 7.30 (d, J = 10.2 Hz, 1H), 6.23 
(dd, J = 10.1, 1.9 Hz, 1H), 6.01 (t, J = 1.7 Hz, 1H), 5.45 (dd, J = 5.0, 1.4 Hz, 1H), 5.23 (s, 1H), 
5.17 (d, J = 17.5 Hz, 1H), 4.90 (d, J = 17.6 Hz, 1H), 4.32 – 4.19 (m, 2H), 4.19 – 4.11 (m, 1H), 2.88 
(dqd, J = 11.5, 7.2, 4.1 Hz, 1H), 2.62 (tdd, J = 13.6, 6.0, 1.7 Hz, 1H), 2.44 – 2.32 (m, 1H), 2.35 – 
2.28 (m, 1H), 2.22 – 2.05 (m, 3H), 1.77 (dt, J = 11.2, 5.2 Hz, 1H), 1.70 – 1.58 (m, 1H), 1.56 (dd, 
J = 13.8, 2.0 Hz, 1H), 1.49 (s, 3H), 1.35 (qd, J = 12.9, 5.0 Hz, 1H), 1.08 (ddd, J = 12.1, 8.2, 4.1 
Hz, 1H), 0.89 (s, 3H), 0.80 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 204.36, 185.30, 
168.28, 167.10, 152.77, 129.03, 124.12, 102.00, 100.61, 90.52, 70.63, 70.34, 69.00, 49.34, 48.09, 
48.05, 47.87, 43.33, 35.69, 35.53, 33.67, 33.51, 31.92, 30.28, 27.32, 23.03, 22.98, 16.31, 15.15, 




5.2.2. General procedure for the synthesis of alkyne-functionalized hyaluronic acid (HA-Alk) 
 
Figure 50: Reaction scheme for the synthesis of alkyne-functionalized HA. 
To a solution of sodium hyaluronate (31 μmol) in 20 mL of 50 mM MES buffer (pH 4.0) was 
added N-hydroxysuccinimide (6.3 mmol) in 5 mL of MES buffer, then EDC (7.8 mmol) in 10 mL 
of MES buffer. The solution was stirred for 5 min before propargylamine (varying amounts) in 
MES buffer was added. The mixture was stirred for 24 hrs at room temperature before being 
dialyzed in 6-8 kDa cutoff dialysis tubing against a 0.9% NaCl solution for 24 hrs, then deionized 
water (4 x 12 hrs). The volume in the bag was frozen at -20°C, then lyophilized to yield a white 
powder. 
 
5.2.3. General procedure for the synthesis of HA-dexamethasone conjugates (HA-Dex) 
 
Figure 51: Reaction scheme for the synthesis of HA-Dex conjugates. 
 To a solution of HA-Alk (1.5 μmol) in deionized H2O was added Dex-N3 (23 μmol) in 
DMSO. A premixed solution of THPTA (20 μmol) and CuSO4 • 5H2O (4 μmol) was then added 
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to the reaction mixture. An aliquot (“pre-NaAsc” sample) was removed for RP-HPLC analysis, 
then NaAsc (81 μmol) was added to the reaction mixture to initiate the reaction. Throughout the 
course of the reaction, additional aliquots were removed for RP-HPLC analysis to determine the 
extent of conjugation. Once the desired conjugation values were achieved, the reaction mixture 
was transferred to a 6-8k dialysis cassette and dialyzed against 1.0 M NaCl (2 x 12 hrs), then 
deionized H2O (5 x 12 hrs). The volume in the cassette was frozen at -20°C and lyophilized to 
yield a white powder. 
 
5.2.4. Analytical Characterization of HA-Dexamethasone Conjugates 
All chromatographic analysis was conducted with a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For RP-HPLC of 
polymer containing samples, general chromatographic conditions employed a linear gradient from 
5-70% acetonitrile in water (constant 0.05% trifluoroacetic acid) was employed over 20 min, with 
a Waters XBridge Protein C4, 3.5 μm, 300 Å stationary phase (4.6 x 150 mm) with a 1.0 mL/min 
flow rate and detection at 214 nm. For semi-preparative HPLC, a linear elution gradient of 
acetonitrile in water over 20 min, with a Waters XBridge BEH C18, 5 μm, 130 Å stationary phase 
(19 x 250 mm), with a 14.0 mL/min flow rate. Semi-preparative method development and reaction 
monitoring was completed on the identical stationary phase in a 4.6 x 250 mm configuration. For 
RP-HPLC analysis of Dex-N3 purity, chromatographic conditions employed a linear gradient from 
5-95% acetonitrile in water (constant 0.05% trifluoroacetic acid) over 60 min, with a Waters 
XBridge C18, 3.5 μm, 130 Å stationary phase (4.6 x 150 mm) using a 1.0 mL/min flow rate at 35°C 
column temperature and detection at 214 nm.  
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LC/MS sample analysis with completed on a Waters Xevo G2, employing linear elution 
gradients of 15-100% acetonitrile in water (constant 0.1% formic acid) over 45 min, employing a 
Waters XBridge BEH C18, 1.7 μm, 130 Å stationary phase (0.075 x 250 mm), and a 0.5 μL/min 
flow rate and 50°C column temperature. Electrospray ionization, operating in the positive mode 
(ESI+), was used as the ionization source with a QTof mass analyzer used for detection.   
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe. All samples were dissolved in 650 μL of D2O or DMSO-d6. 
Data processing was performed using MestReNova 11.0 (Santiago de Compostela, Spain). 
 
5.2.5. Determination of Dex conjugation 
For the quantitative determination of Dex conjugation by RP-HPLC, the following 










)             Equation 2 
where NDex = number of conjugated Dex molecules per backbone, nDex-Az = moles of Dex-N3 used 
in reaction, nHA-Alk = moles of HA-Alk used in reaction, Vpre = total reaction volume before NaAsc 
is added, Vsam = volume of “pre-NaAsc” sample removed from reaction mixture, PAt = measured 
peak area of Dex-N3 at time t, and PAstart = measured peak area of free Dex-N3 before NaAsc is 




5.2.6. Drug release studies 
Dex release studies from HA-Dex were conducted in PBS buffer at 37°C, at a concentration 
of 10 mg/mL. At each time point, an aliquot of the incubated sample solution was removed and 
diluted to a concentration of 1 mg/mL for analysis by RP-HPLC. A linear calibration curve was 
used to quantify Dex release.  
 
5.3. Results and Discussion 
5.3.1. Therapeutic design and rationale 
A polymeric system with chemistry to tune drug loading and be adapted to polymers of 
varying molecular weights is desirable to specifically tailor drug delivery using various OVDs. 
For this reason, the Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC) reaction was 
employed due to the breadth of literature with respect to applications and optimization,32, 34, 208 in 
addition to previous reports of its use with HA.71-72, 209 A small linker was selected to minimize 
the impact of the conjugation chemistry on the functional properties of HA, and to facilitate higher 
Dex loading. In the present work, we selected 16 kDa HA as the polymeric substrate which has an 
adequate balance between relevant mechanical properties in solution, while still allowing detailed 
analytical characterization using techniques such as heteronuclear NMR and HPLC. However, our 
research group has employed this same chemistry to attach payload molecules like Dex to HA with 
a MW in excess of a million daltons.Multiple groups have presented polymer conjugates of 
dexamethasone, forming a hydrazone210-211 at the C3 position, an ester
212-215 at the C21 position, or 
thioether216 at the C21 position. Azide functionality was installed on Dex via esterification at the 
C21-OH position, yielding a degradable bond, which releases the parent Dex molecule over time. 
Importantly, the newly formed ester bond is short to minimize the effect of the added linker on the 
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mechanical properties of HA, and eventual release of Dex yields the same functional moiety, a 
carboxylic acid used for attachment to HA. 
 
Figure 52: Reaction schemes for the synthesis of HA-dexamethasone conjugates: (A) alkyne-functionalization of 
hyaluronic acid, (B) azide-functionalization of dexamethasone, (C) CuAAC conjugation of HA-Alk to Dex-N3. 
 
5.3.2. Synthesis and characterization of conjugates and intermediates 
Azide-functionalization of Dex occurred under anhydrous conditions via esterification of 
the C21-OH in the presence of DIPEA (Figure 52A). The reaction was monitored by analytical RP-
HPLC, and the Dex-N3 product was isolated by semi-preparative RP-HPLC. Structural 
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confirmation of the Dex-N3 product utilized 
1H/13C heteronuclear single quantum coherence 
(HSQC) NMR spectroscopy, which showed a downfield shift of the C21 H’s with the addition of 
a CH2 resonance from the installed linker (Figure 53). Analysis by LC/MS confirms the expected 
mass, and purity analysis by RP-HPLC indicated the compound can be prepared in high purity 
(Figure 54).  
 
Figure 53: HSQC NMR spectrum for Dex-N3 collected in DMSO-d6, where the x-axis is a standard 1H spectrum, and 
the y-axis is a 13C DEPT-135 spectrum. 
HA with an average molecular weight of 16 kDa was used in this study, which contains 
approximately 42 reactive carboxylic acid sites per backbone. Azide- and alkyne-functionalization 
of HA using heterobifunctional linkers via amidation was reported previously.209, 217 Multiple 
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batches of HA-Alk were prepared utilizing propargylamine to install the alkyne moiety on HA 
(Figure 56), with varying degrees of alkyne substitution on the backbone. Dialysis was used as an 
effective purification process due to the significant difference in molecular weight of the 
functionalized HA and unreacted starting materials or reaction byproducts. HSQC NMR 
experiments indicated the presence of the terminal alkyne following functionalization (Figure 55), 
however, due to the overlapping nature of this resonance in both the 1H and 13C spectra (Figure 56 
and Figure 57), quantitation of alkyne functionalization by NMR was not possible. RP-HPLC 
analysis showed an increasing degree of heterogeneity with increasing degree of substitution 
(Figure 58), but no unreacted material was detected following purification.   
 
 





Figure 55: 1H/13C HSQC NMR spectra in D2O for alkyne-functionalized HA, highlighting the presence of a terminal 
alkyne resonance indicating the success of functionalization.  The x-axis is a standard 1H spectrum, and the y-axis is 
a 13C DEPT-135 spectrum.  
The CuAAC reaction was used for the final step to conjugate Dex-N3 and HA-Alk, which requires 
a reducing agent to trigger the reaction through the reduction of Cu2+ to the active Cu1+. This is an 
added benefit for screening numerous reaction conditions on the sub-mg scale since both HA-Alk 
and Dex-N3 can be mixed together without the reaction proceeding. For this reason, analytical RP-
HPLC could be used to determine the amount of conjugated Dex by monitoring the decrease of 
Dex-N3 peak area before and after NaAsc was added to the reaction mixture (Figure 59). Initial 
multi-level reaction development studies were conducted to determine critical parameters, which 
impacted the level of Dex substitution in the final conjugate, varying stoichiometric ratios of Dex-




Figure 56: 1H NMR spectra of various HA-Alk batches. 
 
Figure 57: 1H-decoupled 13C NMR spectra of various HA-Alk batches. 
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Generally, reaction temperature and time showed less of an effect than stoichiometric ratios of the 
reactants, but provided a roadmap to producing HA-Dex conjugates with varying degrees of 
substitution. 1H NMR was used as a secondary measure to quantitatively asses Dex conjugation 
on two larger scale batches used for subsequent studies, showing an average of 2.0 and 4.5 Dex 
 
 
Figure 58: RP-HPLC analysis of HA-Alk batches with varying degrees of stoichiometric equivalents used in the 
reaction. 
  
Table 3: Loading optimization studies of HA-Dex. 
  Stoichiometric Equivalents1 
Reaction Temp Time 10 5 10 20 40 20 40 40 
Ambient 
4 hrs 3.1 3.8 6.1 9.0 
24 hrs 3.0 7.3 6.3 13.9 
37°C 
4 hrs 2.9 4.5 6.2 9.0 
24 hrs 3.1 10.4 6.3 11.0 
50°C 
4 hrs 2.9 4.8 6.2 9.8 
24 hrs 3.3 6.6 6.7 12.2 
1Stoichiometric equivalent values in red refer to propargylamine equivalents used to functionalize HA, and values in 





Figure 59: Representative RP-HPLC analysis employed for optimization of reaction conditions. 
 
Figure 60: 1H NMR spectra of starting HA, alkyne-functionalized HA, and dexamethasone-conjugated HA.  
Resonances highlighted (a-d) were used for quantitative determination of dexamethasone conjugation. 
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per backbone in these batches. Additionally, the presence of a distinct resonance (δ = 8.0 ppm) 
was observed in the 1H NMR spectrum (Figure 60) corresponding to the proton on the newly-
formed 5-membered ring, with the disappearance of the terminal alkyne resonance previously 
observed by HSQC NMR (Figure 61), confirming the success of conjugation. RP-HPLC showed 
dialysis was an effective method at removing unreacted Dex-N3 and other reaction additives. 
 
Figure 61: HSQC NMR spectrum for HA-Dex collected in D2O, where the x-axis is a standard 1H spectrum, and the 
y-axis is a 13C DEPT-135 spectrum. 
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5.3.3. Drug release kinetics  
Release studies in PBS buffer at 37°C conducted on a 2.0 Dex per HA backbone sample 
showed an extended release of Dex from the polymeric system over the course of approximately 
24 hours (Figure 62). A total release of 201 μg Dex from the 10 mg/mL solution was observed, 
thus corroborating the integration values determined by 1H NMR. The release rate may be further 
prolonged by translating to a polymeric system of higher molecular weight than the 16 kDa HA 
used in these studies in addition to performing release studies in more concentrated solutions.  
Further evidence (Section 3.3.4, Error! Reference source not found.) also suggested a strong 
orrelation between release of Dex from the parent Dex-N3 in the presence of phosphate buffer, 
which may be acting as a nucleophile to catalyze ester hydrolysis. 












D e x  R e le a s e  fr o m  H A -D e x

























Figure 62: Release study of Dex from an HA-Dex sample containing an average of 2 Dex per HA backbone.  Study 
conducted at 37°C in PBS buffer, at a concentration of 10 mg/mL HA-Dex. 
Recent research has indicated the need for an alternative therapy in cases where HA and 
Dex are co-administered. Spitzer et al. presented the in vitro efficacy of a physical mixture of HA 
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and Dex, which released Dex for 24 hours.218 Kugelberg et al. reported the in vivo use of a Dex-
coated intraocular lens with post-operative sampling of the aqueous humor over 28 days. White 
blood cell counts and total protein levels were significantly reduced on days 1 and 3 after 
surgery.219 Fiorica et al. recently presented the development of an HA-Dex hydrogel where a β-
cyclodextrin was covalently bound to the HA backbone, enabling the formation of an inclusion 
complex to form with the hydrophobic Dex.220 This resulted in rapid dissolution of Dex from the 
inclusion complex, with approximately 60% of the drug released after 24 hours.   
 Polymer conjugates of Dex have also been presented previously for other therapeutic 
indications. Liu et al. presented a N-(2-hydroxypropyl)methacrylamide (HMPA) conjugate of 
dexamethasone, employing a hydrazone linkage.211 This conjugate showed prolonged release in 
pH 5.0 acetate buffer, with approximately 15% released after 14 days. Importantly, this conjugate 
did not display the same sensitivity to pH 7.4 phosphate buffer as was observed with HA-Dex, 
showing minimal release (~1%) over the same time period. Zacchigna et al. showed a similar 
conjugation strategy as with HA-Dex, by employing a succinic anhydride linker at the C21 position 
of Dex conjugated to a 10 kDa mPEG polymer.215 Interestingly, the release rate was significantly 
slower, with approximately 3.5% released after 24 hours in pH 7.4 phosphate buffer. The release 
rate was greatly enhanced, however, in the presence of porcine esterase, with approximately 45% 
release over the same time period. Similarly, Karkovicova et al. presented a Dex conjugate to 
HMPA, employing a heterobifunctional linker with hydrazone and ester linkages between Dex and 
the polymer.212 The drug release studies were able to differentiate free Dex release from Dex with 
linker, showing approximately 20% ester cleavage over 24 hours in pH 7.4 phosphate buffer.   
 When considering previous reports of polymer-Dex conjugates in the context of the HA-
Dex release rates observed here, there is likely a significant electronic contribution from the 
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adjacent triazole ring which may be accelerating the hydrolysis of the ester in the presence of 
phosphate buffers. The electronic properties of the triazole ring are well studied,221 and the 
potential for modifying release rates are significant. Simply reversing the “polarity” of the 
components, by installing the equivalent alkyne linker on Dex and an azide linker on HA, the 
dipole moment reverses and the release rate may be prolonged. Similarly, by installing electron 
donating or withdrawing substituents at the positions α to the triazole ring, the electrophilic nature 
of the ester carbonyl will be altered and yield a modified release rate for the Dex. Both of these 
approaches may allow for fine tuning of Dex release rates from polymer. 
 
5.4. Conclusions 
The emergence of ophthalmic viscoelastic devices (OVDs) used during cataract surgery 
have significantly improved patient outcomes with respect to minimizing endothelial cell loss. 
Post-operative administration of anti-inflammatory agents such as Dex have reduced the risk of 
inflammation, but suffer from the requirement of frequent administration, which can decrease 
patient compliance. The recent development of co-formulations of HA and Dex have been 
explored. Here, we have presented a novel azide-functionalized Dex derivative suitable for 
covalent conjugation to alkyne-functionalized HA, to optimize drug loading. The release rates of 
Dex in PBS buffer show release over the course of 24 hours in PBS buffer, which could be further 
modulated as desired by modifying the starting the HA molecular weight or solution concentration. 
Additional tuning of release rates may also be possible through modifications to the linker system 
installed on Dex prior to conjugation, as a consequence of the significant electronic contributions 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
6.1. Introduction 
The construction of therapeutic bioconjugates has become an increasingly popular field, 
accompanied by a unique set of applications and challenges. Bioconjugates enable the combination 
of functionalities between multiple different molecules, and permit fine tuning of therapeutic 
action. Throughout this dissertation, a number of key learnings were uncovered in working with 
molecules with a wide range of chemical properties, summarized here in Section 6.2. Through 
these findings, Section 6.3 seeks to present areas of expansion with respect to different disease 
indications, in addition to alternate uses to repurpose molecules (Section 6.3.3) described in this 
dissertation. 
 
6.2. Summary of dissertation chapters  
Chapter 1 presented a background and overview of the dissertation, providing the 
groundwork for the construction of novel bioconjugates for the treatment of antigen-specific 
autoimmune disorders. Autoimmune disorders affect many individuals worldwide, and are unique 
with respect to heterogeneous clinical manifestation and available treatment approaches. An 
additional complication lies in the complexity of the immune system, with a multitude of cells and 
biomolecules involved in disease propagation. The primary drawback to currently approved 
autoimmune therapies is the lack of antigen specificity, which leads to decreased efficacy in 
affected patient populations. This has driven the development of antigen-specific immunotherapies 
(ASIT) to promote improved efficacy and safety profiles for patients. By applying the framework 
of antibody-drug conjugates (ADCs) for targeted delivery, and leveraging the wealth of literature 
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surrounding ADC development, ASIT employing covalent modification to the antigen can provide 
a promising alternative to the available treatment options. 
Chapter 2 outlined the chemistry employed throughout the dissertation, primarily focused 
on the azide-alkyne cycloaddition reaction, with subsequent chemistries appropriate for 
installation of these moieties on molecules with a range of chemical properties. In both compiling 
this review of the literature and presenting findings from the chemical synthesis portions of this 
research, this chapter highlighted the common challenges and often overlooked aspects 
bioconjugate construction. When combining molecules with drastically different chemical 
properties, complications encountered during the development of synthetic routes and analytical 
methods are difficult to predict, but primarily center around solubility, stability, and reactive site 
availability. Additionally, properties of the final conjugate may affect key pharmacokinetic 
parameters, such as clearance and biodistribution, though often overcome through optimization of 
the structure of the bioconjugate. A fundamental understanding of key molecular properties can 
assist in circumnavigating downstream complications in the design and early development stages. 
Chapter 3 presented the development of a novel therapeutic class for the treatment of 
antigen-specific autoimmune disorders, antigen-drug conjugates (AgDCs). Stemming from the 
previous success of ADCs, AgDCs employ the specificity of the antigen for diseased cell 
populations, combined with the potency of a small molecule immunomodulator, to provide an 
ASIT co-delivery strategy for the treatment of experimental autoimmune encephalomyelitis 
(EAE), a murine model of multiple sclerosis (MS). In vivo treatment with antigen-linked 
dexamethasone (PLP139-151-Dex) showed a significant and complete suppression of EAE disease 
symptoms when compared to the control group. This work provides the basis for expansion of this 
concept to include other drug molecules with different mechanisms of action, such as the 
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cytotoxins monomethyl auristatin E (MMAE), mertansine (DM1), and doxorubicin. The synthesis 
and characterization of these AgDCs is complete for potential screening in future studies. 
Importantly, AgDCs are a platform approach with potential to be adapted into other antigen-
specific autoimmune disorders across the disease landscape (Section 6.3.1.2).   
Chapter 4 built off previous research in the construction of Soluble Antigen Arrays 
(SAgAs), which are composed of autoantigen and cell adhesion inhibitor delivered on a polymeric 
support. Studies suggest SAgAs mechanism of action is involved with receptor clustering, thereby 
inhibiting the co-stimulatory activation required to propagate an immune response. Initial SAgA 
development focused on the utilization of an acid-sensitive oxime bond between the peptides and 
the polymer supports, and this work expanded this treatment approach by replacing the 
hydrolyzable bond with a stable covalent linkage, termed ‘click’ SAgAs (cSAgAs). In vivo results 
in the EAE model showed a significant improvement in efficacy of cSAgAs at 25% of the dose of 
SAgAs, providing an alternative to AgDCs that target a different step in the immunological 
cascade of reactions. While the in vivo results for cSAgAs are promising, further optimization of 
key parameters thought to be driving efficacy could provide improved therapeutic outcomes 
(Section 6.3.2). 
Chapter 5 focused on the development of a monotherapeutic alternative to alleviate 
common problems observed in cataract surgery. Viscoelastic substances are solutions of high 
molecular weight polymers commonly employed intraoperatively to limit endothelial cell loss 
(ECL), which ultimately results in reduced patient outcomes. Associated with the use of 
viscoelastic substances is the need to manage postoperative inflammation through anti-
inflammatory compounds such as dexamethasone (Dex), dosed frequently and for extended 
periods of time. This chapter presented the development of a bioconjugate containing covalently 
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linked Dex to the viscoelastic substance as an extended release approach to circumvent the need 
for co-therapy, which can suffer from reduced patient compliance.   
 
6.3. Future directions 
6.3.1. Continuing AgDC development 
6.3.1.1. Tuning MS AgDCs to alter drug release or therapeutic potency 
Considering the in vivo success in mice presented in Chapter 3, there is still a possibility 
of tuning the drug release properties or therapeutic potency of the molecules. Drug release 
influenced by installation of electron withdrawing or electron donating groups in the R position 
provide the potential for tuning as desired (Figure 63). 
 
Figure 63: Potential for modulating drug release rate through installation of EWD or EDG at R.   
Kuchroo et al. presented a study focused on identifying key residues in the PLP139-151 peptide 
epitope sequence which were critical for binding by observing the effect of single amino acid 
substitutions on T cell proliferation.99 Given the relatively short linker installed in the PLP139-151-
Dex conjugate, using a slightly longer PEGylated linker between the antigen and drug can 
potentially provide additional flexibility and spacing to increase the binding affinity of the 
conjugate for the receptor. Additionally, modifying the peptide antigen to epitopes derived from 
other myelin sheath proteins known to cause disease,7 such as myelin basic protein (MBP) or 
myelin oligodendrocyte glycoprotein (MOG) could potentially target different immune cell 
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populations and provide a response which is different than that based on the PLP autoantigen. 
Finally, utilizing cytotoxic drugs linked to the peptide, such as MMAE, DM1, or doxorubicin, have 
the potential to provide apoptotic cellular response as opposed to the tolerogenic response 
proposed with dexamethasone. 
 
6.3.1.2. Adaption to other therapeutic areas 
The AgDC platform approach has the potential for translation to a significant number of 
antigen-specific autoimmune disorders with known disease-causing autoantigens. Table 4 
provides an example of the potential translation of AgDCs across the therapeutic landscape. 
Table 4: Potential antigen-specific autoimmune disorders suitable for the AgDC platform 
Autoimmune Disease Antigen 
Multiple Sclerosis PLP, MBP, MOG 
Type 1 Diabetes Insulin, IA-2, GAD-65 
Celiacs Disease TG2 
Graves Disease TSHR 
Myasthenia Gravis nAChR, MuSK, LRP4 
Hashimotos Encephalomyelitis DDAHI, AKIPIAI 
Neuromyelitis Optica AQP4, MOG 
Rheumatoid Arthritis Collagen, Aggrecan 
 
Ideally, full length protein autoantigen would be the most suitable target for the AgDC platform, 
but as is the case with MS, antigenic peptide epitopes are also capable of triggering an immune 
response.7 Full length protein would follow the same internalization pathway via receptor-
mediated endocytosis, then following processing by the antigen presenting cell (APC), the peptide 
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epitope is presented on the surface in the major histocompatibility complex (MHC class II) for 
subsequent T cell activation.1 It is unknown whether peptide antigens would follow the same APC 
internalization and presentation pathway, but given that they are capable of inducing an immune 
response, binding in the MHC class II-T cell receptor pocket is likely. Further studies employing 
both peptide and full length protein autoantigens equipped with a probe molecule such as a 
fluorophore or radiolabel would permit tracking the cellular localization to elucidate this 
mechanism. Efforts to express and purify full length proteolipid protein (PLP) autoantigen used in 
this work were unsuccessful due to solubility issues stemming from the transmembrane α-helical 
domains. Current efforts by other researchers in the group focus on adapting the AgDC platform 
to other antigen-specific autoimmune disorders. 
 
6.3.2. Continuing SAgA development 
Given the polymeric nature and accompanying heterogeneity of the therapeutic platform, 
(c)SAgAs have a number of key variables appropriate for tuning their activities. Peptide valency, 
or the number of peptides displayed on a single polymer backbone, is a critical factor in antigen 
binding to T cells.222 Altering antigen valency through modification of reaction conditions has the 
potential to alter the observed immune response. Similarly, the implications of size on 
biodistribution of SAgA molecules has been studied,29 and using polymer supports with different 
molecular weights could provide a varied immune response. Additionally, screening the effect of 
administration route on biodistribution and efficacy of cSAgA treatments, probably aided by 
incorporation of a tracer molecule prior to in vivo treatment, could assist in better understanding 
the molecular mechanisms behind increased efficacy of cSAgAs over SAgAs. Finally, as with the 
AgDC platform, SAgAs also have the potential for direct translation to other therapeutic 
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indications by modifying the sequence of the attached peptides for those applicable to another 
antigen-specific autoimmune disorder (Table 4). This work is currently underway on the cSAgA 
platform by other researchers in the group. 
 
6.3.3. Diagnostic assays: capturing antigen-specific cells or antibodies 
One of the benefits to employing click chemistry for bioconjugation applications is the 
large toolbox of commercial azide- and alkyne-functionalized materials available to the researcher, 
in addition to the significant literature precedence of the reaction across many disciplines. This 
section focuses on applications to repurpose molecules synthesized in this dissertation, and to 
present concepts to further elucidate mechanisms involved in immune responses.   
Numerous groups have described the functionalization of surfaces with azide or alkyne 
(terminal and strained) moieties,50, 92, 223-224 presenting a method of attaching the peptide antigens 
described here to a solid surface. Similar in concept to a sandwich ELISA assay, quantification of 
antigen-specific cells or autoantibodies in a mixed cell population such as those isolated from EAE 
mice could permit a better understanding of the cell types and biomolecules that are contributing 
to an immune response. Commercially available surface functionalized plates typically involve 
‘proprietary’ electrophilic groups similar to the NHS ester (Section 2.3) to non-specifically attach 
antigens via lysine residues or the N-terminus. By using a slight modification to this procedure, 
antigen attachment via click chemistry ensures linkage occurs at the N-terminus, with less 




Figure 64: Overview of peptide attachment to functionalized plates, with an alternative route via click chemistry which 
ensures proper orientation and adequate spacing of the peptide antigen from the plate surface. 
Perhaps more intriguing is a small modification to the strained alkyne approach, by synthesizing a 
photolabile variant which reveals the active functionality under exposure to 350 nm light (Figure 
65).49 This permits the site specific conjugation of the biomolecule following release of the caging 
group. Applying this concept to functionalized plates, the potential for a high throughput method 
of assaying antigen-specificity in mixed cell populations exists. 





Figure 65: Synthesis of a photolabile variant of the strained alkyne, presented by Arumugam et al.49 
The implementation of magnetic beads to support biomolecules for catalysis and isolation 
has gained recent traction, and azide- or alkyne-functionalized beads are both commercially 
available and presented in the literature.225 After attachment of the peptide autoantigen to the 
magnetic bead, antigen-specific cells or autoantibodies can be isolated after mixing with a 
biological sample and applying a magnetic field. While techniques like flow cytometry are able to 
identify these antigen-specific cell populations, magnetic beads provide an attractive method of 
collecting these cell populations or antibodies implicated in disease for further studies.   
 
6.4. Conclusions 
The work presented both in this section and throughout the dissertation provides a 
framework for the continued development of novel treatment approaches for antigen-specific 
autoimmune disorders. Utilizing the power of the azide-alkyne cycloaddition reaction and its 
variants, the creation of a toolbox of functionalized molecules has enabled facile access to 
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construction of biomolecule and materials for a variety of uses. It is hoped that further elucidation 
of mechanisms and tuning of molecular properties throughout these platforms leads to treatment 
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